EARLY TESTING PRECLINICAL DEVELOPMENT CLINICAL TRIALS CONTACT ABOUT IRIS PHARMA WHO WE ARE WHY US SERVICES OCULAR EXPERTISE PUBLICATIONS NEWS & MEDIA EVENTS Publications Preclinical Efficacy Preclinical Pharmacokinetics Ocular tolerance & safety Clinical Research Devices & Evaluations PRECLINICAL EFFICACY #2021-243 Comparison of two experimental mouse dry eye models through inflammatory gene set enrichment analysis based on a multiplexed transcriptomic approach KESSAL K (a),(b),(c), DAULL P (d), CIMBOLINI N (e), FERAILLE L (e), GRILLO S (e), DOCQUIER M (f), BAUDOUIN C (a),(b),(c),(g), BRIGNOLE-BAUDOUIN F (a),(b),(c),(h), GARRIGUE JS (d) Int. J. Mol. Sci. 2021; 22, 10770. https://doi.org/10.3390/ijms221910770 (a) INSERM UMR 968, CNRS UMR 7210, Institut de la Vision, IHU ForeSight, Sorbonne Université UM80, Paris, France - (b) Centre Hospitalier National d’Ophtalmologie des Quinze-Vingts, INSERM-DGOS CIC1423, IHU FOReSight, Paris, France - (c) Centre Hospitalier National d’Ophtalmologie des Quinze-Vingts, Paris, France - (d) SANTEN SAS, Evry, France - (e) IRIS PHARMA, La Gaude, France - (f) iGE3 Genomics Platform, University of Geneva, Geneva, Switzerland - (g) Ambroise Paré, APHP, Department of Ophthalmology, University Paris Saclay, Boulogne, France - (h) Faculté de Pharmacie, Université de Paris, Paris, France ⇒ Article #2021-240 Assessment of a new nanostructured microemulsion system for ocular delivery of Sorafenib to posterior segment of the eye SANTONOCITO M (a), ZAPPULLA C (a), VIOLA S (a), LA ROSA LR (a), SOLFATO E (a), ABBATE I (a), TARALLO V (b), APICELLA I (b), PLATANIA CBM (c), MAUGERI G (c), D’AGATA V (c), BUCOLO C (c), DE FALCO S (b), MAZZONE MG (a), GIULIANO F (a) Int. J. Mol. Sci. 2021; 22, 4404. https://doi.org/10.3390/ijms22094404 (collaboration) (a) SIFI S.p.A., Catania, Italy - (b) Institute of Genetics and Biophysics, CNR, Napoli, Italy - (c) Department of Biomedical and Biotechnological Sciences, University of Catania, Italy ⇒ Article #2021-239 Review of preclinical outcomes of a topical cationic emulsion of cyclosporine A for the treatment of ocular surface diseases DAULL P (a), BAUDOUIN C (b), LIANG H (c), FERAILLE L (d), BARABINO S (e), GARRIGUE JS (a) Ocul. Immunol. Inflamm. 2021. Aug 4;1-11 doi: 10.1080/09273948.2021.1957124 (a) SANTEN SAS, Evry, France - (b) CHNO des Quinze-Vingts, IHU FOReSIGHT, INSERM-DGOS CIC 1423, Paris, France - (c) Sorbonne Universités, INSERM, CNRS, Institut de la Vision, Paris, France - (d) IRIS PHARMA, La Gaude, France - (e) OCULAR SURFACE & DRY EYE CENTER, University of Milan, Italy ⇒ Article #2021-238 MPS VI associated ocular phenotypes in an MPS VI murine model and the therapeutic effects of odiparcil treatment ENTCHEV E (a), ANTONELLI S (b), MAURO V (b), CIMBOLINI N (b), JANTZEN I (a), ROUSSEY A (a), GERMAIN JM (a), ZHANG H (c), LUCCARRINI JM (a), LACOMBE O (a), YOUNG S (c)(d), FERAILLE L (b), TALLANDIER M (a) Mol. Genet. Metab. 2021. doi: 10.1016/j.ymgme.2021.07.008 (pre-print on July 25, 2021) (a) INVENTIVA PHARMA, Daix, France, (b) IRIS PHARMA, La Gaude, France, (c) DUKE UNIVERSITY HEALTH SYSTEM BIOCHEMICAL GENETICS LAB, Durham, NC, USA, (d) DUKE SCHOOL OF MEDICINE, Durham, NC, USA ⇒ Article #2021-237 A rare natural lipid induces neuroglobin expression to prevent amyloid oligomers toxicity and retinal neurodegeneration OAMEN HP (a), ROMERO N (a), KNUCKLES P (b), SAARIKANGAS J (c), DONG Y (d), CAUDRON F (a) doi: 10.1101/2021.06.23.449608 (pre-print on June 23, 2021) (collaboration) (a) SCHOOL OF BIOLOGICAL SCIENCES, London, UK, (b) FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH, Basel, Switzerland, (c) HELSINKI INSTITUTE OF LIFE SCIENCE, Helsinki, Finland; Research Programme in Molecular and Integrative Biosciences, University of Helsinki, Finland; Neuroscience Center, University of Helsinki, Finland (d) SUNREGEN HEALTHCARE AG, Reinach, Switzerland ⇒ Article #2021-236 Ocular surface response of two preservative-free cylcosporine A emulsion eye drops in a mouse model of dry eye DAULL P (a), NAGANO T (b), GROS E (c), FERAILLE L (c), BARABINO S (d), GARRIGUE JS (a) Curr. Eye Res. 2021. doi: 10.1080/02713683.2021.1878228 (a) SANTEN SAS, Evry, France - (b) SANTEN Pharmaceutical Co., Ltd., Osaka, Japan - (c) IRIS PHARMA, La Gaude, France - (d) OCULAR SURFACE & DRY EYE CENTER, University of Milan, Italy ⇒ Article #2021-235 DutaFabs are engineered therapeutic Fab fragments that can bind two targets simultaneously BECKMANN R (a), JENSEN K (a), FENN S (a) et al. Nature 2021; 12, 708. doi: 10.1038/s41467-021-20949-3 (collaboration) (a) ROCHE PHARMA Research and Early Development, Penzberg, Germany ⇒ Article #2020-231 Thermostable small-molecule inhibitor of angiogenesis and vascular permeability that suppresses a pERK-FosB/ΔFosB–VCAM-1 axis Y LI (a), A ALHENDI (a), MC YEH (a), M ELAHY (a), F SANTIAGO (a), N DESHPANDE (b), B WU (a), E CHAN (a), S INAM (a), L PRADO-LOURENCO (a), J MARCHAND (c), R JOYCE (c), L WILKINSON-WHITE (d), M RAFTERY (e), M ZHU (f), (g), (h), S ADAMSON (h), F BARNAT (i), K VIAUD-QUENTRIC (i), J SOCKLER (j), J MACKAY (k), A CHANG (g), (h), (l), P MITCHELL (m), S MARCUCCIO (c), (n), L KHACHIGIAN (a) Sci. Adv. 2020; 6 : eaaz7815 doi: 10.1126/sciadv.aaz7815 (a) Vascular Biology and Translational Research, UNIVERSITY OF NEW SOUTH WALES, Sydney, Australia (b) Systems Biology Initiative, UNIVERSITY OF NEW SOUTH WALES, Sydney, Australia – (c) ADVANCED MOLECULAR TECHNOLOGIES Pty Ltd, Scoresby, Australia – (d) Sydney Analytical Core Facility, UNIVERSITY OF SYDNEY, Australia – (e) Bioanalytical Mass Spectrometry Facility, UNIVERSITY OF NEW SOUTH WALES, Sydney, Australia – (f) New South Wales Tissue Bank, Kogarah, Australia – (g) SAVE SIGHT INSTITUTE, University of Sydney, Australia – (h) GREENLIGHT CLINICAL Pty. Ltd., Woolloomooloo, Australia – (i) IRIS PHARMA, La Gaude, France – (j) DATAPHARM AUSTRALIA Pty. Ltd., Drummoyne, Australia – (k) School of Life and Environmental Sciences, UNIVERSITY OF SYDNEY, Australia – (l) Sydney Eye Hospital, Australia – (m) Centre for Vision Research, WESTMEAD INSTITUTE OF MEDICAL RESEARCH, Westmead, Australia – (n) La Trobe Institute for Molecular Science, Melbourne, Australia. ⇒ Article #2020-230 SBC003 demonstrates neuroprotective effects in a murine model of N-nitroso-N-methylurea (NMU) induced photoreceptor degeneration DONG Y (a), HARKIN K (b), FERAILLE L (c), CHEN M (b), XU H (b) Invest. Ophthalmol. Vis. Sci. 2020;61(7):2475. (a) SUNREGEN HEALTHCARE AG, Allschwil, Switzerland - (b) QUEEN'S UNIVERSITY BELFAST, United Kingdom - (c) IRIS PHARMA, La Gaude, France ⇒ Abstract #2020-229 The uni-nephrectomized and salt-loaded SDT fatty rat, a novel type 2 diabetic model of diabetic nephropathy, develops features of diabetic retinopathy SHINOHARA M (a), BRIAND F (b), ANTONELLI S (c), MAURO V (c), CIMBOLINI N (c), BROUSSEAU E (b), OHTA T (d), MIYAJIMA K (e), KAGEYAMA Y (a), FERAILLE L (c), SULPICE T (b) Japanese Society of Toxicologic Pathology meeting 2020; Tokuo, JAPAN (a) CLEA Japan Inc., Tokyo, Japan - (b) PHYSIOGENEX, Labege, France - (c) IRIS PHARMA, La Gaude, France - (d) Kyoto University, Kyoto, Japan - (e) Tokyo University of Agriculture, Tokyo, Japan #2019-222 Modulation of inflammation-related genes in the cornea of a mouse model of dry eye upon treatment with cyclosporine eye drops DAULL P (a), BARABINO S (b), FERAILLE L (c), KESSAL K (d), DOCQUIER (e), PARSADANIANTZ S (d), BAUDOUIN C (d,f), GARRIGUE JS (a) Curr. Eye Res. 2019 Jan 21:1-10. doi: 10.1080/02713683.2018.1563197. (a) SANTEN SAS, Evry, France - (b) OCULAR SURFACE & DRY EYE CENTER, University of Milan, Italy - (c) IRIS PHARMA, La Gaude, France - (d) INSTITUT DE LA VISION, Paris, France - (e) iGE3 Genomics Platform, University of Geneva, Switzerland - (f) Quinze-Vingts National Ophthalmology Hospital, Paris, France ⇒ Article ⇒ Abstract #2019-221 Chronic model of uveitis in rabbit - Efficacy of Triamcinolone Acetonide QUENTRIC Y (a), ANTONELLI S (a), MAURO V (a), CIMBOLINI N (a), FERAILLE L (a), ELENA PP (a) ARVO meeting 2019; Vancouver - CANADA. Invest. Ophthalmol. Vis. Sci. 2019; 60(9):800. doi: (a) IRIS PHARMA, La Gaude, France ⇒ Poster ⇒ Abstract #2019-220 Efficacy of preservative-free cyclosporine emulsion eye drops in a mouse model of dry eye DAULL P (a) , NAGANO T (b), OKADA S (b), GROS E (c), FERAILLE L (c), GARRIGUE JS (a) ARVO meeting 2019; Vancouver - Canada. Invest. Ophthalmol. Vis. Sci. 2019; 60(9):292. doi: (a) SANTEN SAS, Evry, France - (b) SANTEN Ltd., Osaka, Japan - (c) IRIS PHARMA, La Gaude, France ⇒ Poster ⇒ Abstract #2019-219 Dry Eye: Efficacy evaluation of two synthetic peptides from Chondrocyte Derived ExtraCellular Matrix (CDEM) in comparison to lifitegrast, cyclosporine A, diquafosol sodium and sodium hyaluronate in a murine model of dry eye BAIK T (a), CHOI J (a), MIN K (a), FERAILLE L (b), RAYMOND E (b), ELENA PP (b) ARVO meeting 2019; Vancouver - Canada. Invest. Ophthalmol. Vis. Sci. 2019; 60(9):291. doi: (a) YUYU PHARMA, Seoul, The Republic of Korea - (b) IRIS PHARMA, La Gaude, France ⇒ Abstract #2019-218 Comparison of inflammatory gene networks in dry eye between human and mouse KESSAL K (a,b), DAULL P (c), FERAILLE L (d), CIMBOLINI N (d), LIANG H (a,b), DOCQUIER (e), BARABINO S (f), MELIK PARSADANIANTZ S (a), GARRIGUE JS (c), BAUDOUIN C (a,b), BAUDOUIN F (a,b) ARVO meeting 2019; Vancouver - Canada. Invest. Ophthalmol. Vis. Sci. 2019; 60(9):274. doi: (a) INSTITUT DE LA VISION, Paris, France - (b) Quinze-Vingts National Ophthalmology Hospital, Paris, France - (c) SANTEN SAS, Evry, France - (d) IRIS PHARMA, La Gaude, France - (e) iGE3 Genomics Platform, University of Geneva, Switzerland - (f) CLINICA OCULISTICA, Genova, Italy ⇒ Abstract #2018-241 Topical Administration of Spironolactone-Loaded Nanomicelles Prevents Glucocorticoid-Induced Delayed Corneal Wound Healing in Rabbits DAHMANA N (a), MUGNIER T (b), GABRIEL D (b), KALTSATOS V (c), BERTAIM T (c), BEHAR-COHEN F (d,e), GURNY R (a,b), KALIA Y (a) (collaboration) Mol Pharm. 2018 Mar 5; 15(3):1192-1202. doi: 10.1021/acs.molpharmaceut.7b01028 (a) University of Geneva & University of Lausanne , Geneva, Switzerland – (b) APIDEL SA, Geneva, Switzerland – (c) CEVA Santé Animal , Libourne , France – (d) Fondation Asile des Aveugles , Hôpital Ophtalmique Jules-Gonin , Lausanne , Switzerland – (e) INSERM, UMRS 872 Team 17, Paris, France ⇒ Abstract #2018-215 Safety and Tolerability of Overdosed Artificial Tears by Abraded Rabbit Corneas DAULL P (a), RAYMOND E (b), FERAILLE L (b), GARRIGUE JS (a) J. Ocul. Pharmacol. Ther. 2018; doi: 10.1089/jop.2018.0040 (a) NOVAGALI Innovation Center, SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France ⇒ Article #2018-214 The uni-nephrectomized SDT fatty rat, a novel type 2 diabetic model of diabetic nephropathy, develops features of diabetic retinopathy over 10 weeks BRIAND F (a), ANTONELLI S (b), MAURO V (b), CIMBOLINI N (b), SHINOHARA M (c), BROUSSEAU E (a), OHTA T (d), KAGEYAMA Y (c), FERAILLE L (b), SULPICE T (a) ARVO meeting 2018; Hawaii - USA. Invest. Ophthalmol. Vis. Sci. 2018; 59(9):3573. doi: (a) PHYSIOGENEX, Labege, France - (b) IRIS PHARMA, La Gaude, France - (c) CLEA Japan Inc., Tokyo, Japan - (d) JAPAN TOBACCO Inc., Osaka, Japan ⇒ Poster ⇒ Abstract #2017-210 Comparative efficacy of preservative-free anti-inflammatory eye drops in a mouse model of dry eye GARRIGUE JS (a), CIMBOLINI N (b), KESSAL K (c), GROS E (b), MAURO V (b), BARABINO S (d), BAUDOUIN C (c), DAULL P (a) ARVO meeting 2017; Baltimore - USA. Invest. Ophthalmol. Vis. Sci. 2017; 58(8): 800. doi: (a) NOVAGALI Innovation Center, SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France - (c) INSTITUT DE LA VISION, Paris, France - (d) CLINICA OCULISTICA, Genoa, Italy ⇒ Abstract #2017-209 Conditional self-knockout of otx2 mice: a new model for late-onset neuronal degeneration ELENA PP (a), ANTONELLI S (a), MAURO V (a), CIMBOLINI N (a), LAMONERIE T (b), FERAILLE L (a) ARVO meeting 2017; Baltimore - USA. Invest. Ophthalmol. Vis. Sci. 2017; 58(8):4532. doi: (a) IRIS PHARMA, La Gaude, France - (b) UNIVERSITE DE NICE, Nice, France ⇒ Abstract #2017-208 Corneal transcriptome changes in a mouse model of dry eye DAULL P (a), FERAILLE L (b), KESSAL K (c), ELENA PP (b), BARABINO S (d), BAUDOUIN C (c), GARRIGUE JS (a) ARVO meeting 2017; Baltimore - USA. Invest. Ophthalmol. Vis. Sci. 2017; 58(8): 797. doi: (a) NOVAGALI Innovation Center, SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France - (c) INSTITUT DE LA VISION, Paris, France - (d) CLINICA OCULISTICA, Genoa, Italy ⇒ Abstract #2016-223 Efficacy of a preservative-free cationic emulsion vehicle eye drop in a mouse model of dry eye QUENTRIC Y (a), DAULL P (b), FERAILLE L (a), ELENA PP (a), GARRIGUE JS (b) ARVO meeting 2016; Seattle - USA. Invest. Ophthalmol. Vis. Sci. 2016; 57: 422. doi: (a) IRIS PHARMA, La Gaude, France - (b) NOVAGALI Innovation Center, SANTEN SAS, Evry, France ⇒ Poster #2016-205 Norbixin Protects Retinal Pigmented Epithelium Cells and Photoreceptors against A2E-Mediated Phototoxicity In Vitro and In Vivo FONTAINE V (a), MONTEIRO E (a), BRAZHNIKOVA E (a), LESAGE L (a), BALDUCCI C (b), GUIBOUT L (b), FERAILLE L (c), ELENA PP (c), SAHEL JA (a), VEILLET S (b), LAFONT R (b) PLOS ONE 11(12): e0167793. doi: 10.1371/journal.pone.0167793 (a) INSTITUT DE LA VISION, Paris, France - (b) BIOPHYTIS, Paris, France - (c) IRIS PHARMA, La Gaude, France ⇒ Article #2016-204 Efficacy of a new topical cationic emulsion of cyclosporine A on dry eye clinical signs in an experimental mouse model of dry eye DAULL P (a), FERAILLE L (b), BARABINO S (c), CIMBOLINI N (b), GRILLO-ANTONELLI S (b), MAURO V (b), GARRIGUE JS (a) Exp. Eye Res. 2016 Oct 21; 153:159-164 (a) NOVAGALI Innovation Center, SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France - (c) CLINICA OCULISTICA, Genoa, Italy ⇒ Article #2016-201 SMA+ perivascular cells evaluation in VEGF induced blood-retinal barrier breakdown in rabbit model ELENA PP (a), MAURO V (a), GRILLO-ANTONELLI S (a), CIMBOLINI N (a), VIAUD-QUENTRIC K (a), FERAILLE L (a) EVER meeting 2016; Nice - France. (a) IRIS PHARMA, La Gaude, France ⇒ Poster ⇒ Abstract #2016-200 Pre-clinical in vivo (animal) testing of ocular formulations and drug delivery systems ELENA PP (a) Ocular Drug Delivery; Berlin - Germany. Oral communication (a) IRIS PHARMA, La Gaude, France #2016-199 Comparative efficacy of cyclosporine eye drop formulations in a mouse model of dry eye GARRIGUE JS (a), DAULL P (a), FERAILLE L (b), BARABINO S (c) ARVO meeting 2016; Seattle - USA. Invest. Ophthalmol. Vis. Sci. 2016; 57(12): 421. doi: (a) SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France - (c) CLINICA OCULISTICA, Genoa, Italy ⇒ Poster #2016-198 BIO201: a new drug candidate for the treatment of dry AMD FONTAINE V (a), BRAZHNIKOVA E (a), MONTEIRO E (a), LESAGE L (a), BALDUCCI C (b), GUIBOUT L (b), FERAILLE L (c), ELENA PP (c), SAHEL JA (a), VEILLET S (b), LAFONT R (b) ARVO meeting 2016; Seattle - USA. Invest. Ophthalmol. Vis. Sci. 2016; 57: 1119. doi: (a) INSTITUT DE LA VISION, Paris, France - (b) BIOPHYTIS, Paris, France - (c) IRIS PHARMA, La Gaude, France ⇒ Poster #2016-196 Comparison of the anti-inflammatory effects of artificial tears in a rat model of corneal scraping DAULL P (a), FERAILLE L (b), ELENA PP (b), GARRIGUE JS (a) J. Ocul. Pharmacol. Ther. 2016; doi: 10.1089/jop.2015.0054 (a) SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France ⇒ Article #2015-216 HL036337 Ophthalmic Solution: Topical TNF Blocker for Dry Eye Disease Protein and AntiboPEGS meeting 2015 Boston, MA (collaboration) HanAll BioPharma Co., Ltd, Seoul, Korea #2015-195 Cationic emulsion of cyclosporine for the management of ocular surface inflammation: a preclinical evaluation DAULL P (a), FERAILLE L (b), AMRANE M (a), ELENA PP (b), GARRIGUE JS (a) IOIS meeting 2015; San Francisco – USA (a) NOVAGALI Innovation Center, SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France ⇒ Poster #2015-194 Comparison of CKC- and BAK-cationic emulsions in a rat model of corneal wound healing DAULL P (a), FERAILLE L (b), ELENA PP (b), GARRIGUE JS (a) EVER meeting 2015; Nice – France. Poster T034 (a) NOVAGALI Innovation Center, SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France ⇒ Abstract #2015-193 Evaluation of a cyclosporine A ophthalmic ointment in an experimental mouse model of dry eye CIMBOLINI N (a), GRILLO-ANTONELLI S (a), MAURO V (a), FERAILLE L (a), ELENA PP (a) EVER meeting 2015; Nice – France. Poster T031 (a) IRIS PHARMA, La Gaude, France ⇒ Poster #2015-192 Efficacy evaluation of a cationic emulsion of cyclosporine in a mouse model of dry eye DAULL P (a), FERAILLE L (b), BARABINO S (c), GARRIGUE JS (a) ARVO meeting 2015; Denver, CO - USA. Invest. Ophthalmol. Vis. Sci. 2015; 56: 4468. doi: (a) NOVAGALI Innovation Center, SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France - (c) CLINICA OCULISTICA, Genoa, Italy ⇒ Abstract #2015-191 Effects of the multi-kinase inhibitor regorafenib on ocular neovascularization KLAR J (d), BOETTGER M (a,d), FREUNDLIEB J (c), KELDENICH J (c), ELENA PP (b), VON DEGENFELD G (d) ARVO meeting 2015; DENVER, CO - USA. Invest. Ophthalmol. Vis. Sci. 2015; 56(7): 426.92. doi: (a) Clinical Sciences Experimental Medicine, BAYER PHARMA AG, Wuppertal, Germany - (b) IRIS PHARMA, Nice, France - (c) BAYER PHARMA AG, Wuppertal, Germany - (d) Ophthalmology, BAYER PHARMA AG, Wuppertal, Germany ⇒ Abstract #2015-190 Comparison of the effect of Dexamethasone and Prednisolone Acetate in a rat model of glucocorticoid-induced ocular hypertension following topical delivery ELENA PP (a), CIMBOLINI N (a), GRILLO-ANTONELLI S (a), BOUZIN M (a), FERAILLE L (a), VIAUD-QUENTRIC K (a), NICOLAS MF (b), LAURENT S (c), BLOT C (c) ARVO meeting 2015; DENVER, CO - USA. ARVO e-abstract No. 2001 - Poster D0244 (a) IRIS PHARMA, Nice, France - (b) SANOFI R&D - LGCR, Vitry-sur-Seine, France - (c) SANOFI R&D - Ophthalmology Unit, Paris, France ⇒ Abstract #2014-224 Systemic treatment with glutathione PEGylated liposomal methylprednisolone (2B3-201) improves therapeutic efficacy in a model of ocular inflammation Invest. Ophthalmol. Vis. Sci 2014; 55: 2859. doi: (collaboration) TO-BBB TECHNOLOGIES BV, Leiden, Netherlands ⇒ Article #2014-188 The effect of preservatives and antiglaucoma treatments on the ocular surface of mice with dry eye BARABINO S (a), GRILLO-ANTONELLI S (b), CIMBOLINI N (b), MAURO V (b), BOUZIN M (b) Invest. Ophthalmol. Vis. Sci. 2014; 55: 6499-6504 doi:10.1167/iovs.14-14548 (a) CLINICA OCULISTICA, Genoa, Italy - (b) IRIS PHARMA, Nice, France ⇒ Article #2014-187 Two simple animal models of intraocular pressure elevation for testing therapeutic drugs in glaucoma GRILLO-ANTONELLI S (a), CIMBOLINI N (a), FERAILLE L (a), ELENA PP (a) EVER meeting 2014; Nice – France. Poster T017 (a) IRIS PHARMA, Nice, France ⇒ Poster ⇒ Abstract #2013-181 Dry eye: two experimental rodent models for drug development CIMBOLINI N (a), ANTONELLI S (a), BARABINO S (b), FERAILLE L (a), MARGARON P (a), ELENA PP (a) TFOS meeting 2013; Taormina - Sicily - Italy (a) IRIS PHARMA, Nice, France - (b) CLINICA OCULISTICA, Genoa, Italy ⇒ Poster #2013-180 Effects of cyclosporine in an experimental rat model of dry eye CIMBOLINI N (a), ANTONELLI S (a), FERAILLE L (a), MARGARON P (a), ELENA PP (a) EVER meeting 2013; Nice – France. Poster S008 (a) IRIS PHARMA, Nice, France ⇒ Poster ⇒ Abstract #2013-179 Impact of the routes of administration on the effects of cyclosporine in an experimental rat model of dry eye CIMBOLINI N (a), GRILLO-ANTONELLI S (a), FERAILLE L (a), MARGARON P (a), ELENA PP (a) ISOPT meeting 2013; Paris – France (a) IRIS PHARMA, Nice, France ⇒ Poster #2013-176 Comparison of two rodent models of dry eye induced by Scopolamine ELENA PP (a), CIMBOLINI N (a), ANTONELLI S (a), FERAILLE L (a), BARABINO S (b), MARGARON P (a) ARVO meeting 2013; Seattle, WA - USA. ARVO e-abstract No. 6002 - Poster A0065 (a) IRIS PHARMA, Nice, France - (b) CLINICA OCULISTICA, Genoa, Italy ⇒ Abstract #2012-173 Protection of blue light induced retinal degeneration by the free radical scavenger Phenyl-N-tert-butylnitrone and a serotonin receptor 5-HT1a agonist in rats GRILLO-ANTONELLI S (a), CIMBOLINI N (a), DUBOS H (a), FERAILLE L (a), MARGARON P (a), ELENA PP (a) EVER meeting 2012; Nice - France. Poster S063 (a) IRIS PHARMA, Nice, France ⇒ Poster ⇒ Abstract #2012-172 Comparison of the anti-inflammatory effects of artificial tears in a rat model of corneal scraping DAULL P (a), FERAILLE L (b), ELENA PP (b), BAUDOUIN C (c), GARRIGUE JS (a) EVER meeting 2012; Nice - France. Poster T036 (a) NOVAGALI PHARMA SA, Evry, France - (b) IRIS PHARMA, Nice, France - (c) INSTITUT DE LA VISION, Paris, France ⇒ Abstract #2012-171 Ocular surface effects of antiglaucoma combination therapies in a rat model of corneal scraping DAULL P (a), GARRIGUE JS (a), FERAILLE L (b), BAUDOUIN C (c), ELENA PP (b) EVER meeting 2012; Nice - France. Poster T037 (a) NOVAGALI PHARMA SA, Evry, France - (b) IRIS PHARMA, Nice, France - (c) INSTITUT DE LA VISION, Paris, France ⇒ Abstract #2012-170 Multiple topical administrations of Ramipril enhance retinal ganglion cell survival after transient retinal ischemia-reperfusion in rats ELENA PP (a), VIAUD-QUENTRIC K (a), CHARFEDDINE R (b), REKIK R (b) EVER meeting 2012; Nice - France. Poster F029 (a) IRIS PHARMA, Nice, France - (b) UNIMED, Sousse, Tunisie - (c) Ophthalmology Clinic, Tunis, Tunisia ⇒ Abstract #2012-168 Anti-inflammatory Effects Of Glucocorticoids On Endotoxin-induced Uveitis (EIU) In Rats: Impact Of The Mode Of Administration ELENA PP (a), CIMBOLINI N (a), ANTONELLI S (a), DUBOS H (a), FERAILLE L (a), MARGARON P (a) ARVO meeting 2012; Fort Lauderdale, FL - USA. ARVO e-abstract No. 6285 - Poster D1145 (a) IRIS PHARMA, Nice, France ⇒ Poster #2012-167 Assessment of Intra-Ocular Pressure lowering effect of novel gel formulations of Latanoprost and Timolol in nonhuman primates following topical delivery GOODY RJ (a), WHITTAKER S (a), HENRY S (a), BROOKES R (a), STRUHARIK M (a), BERMON F (b), MARGARON P (b), POLZER H (c), LAWRENCE MS (a) ARVO meeting 2012; Fort Lauderdale, FL - USA. ARVO e-abstract No. 1968 - Poster D812 (a) RXGEN, Hamden, CT, USA - (b) IRIS PHARMA, Nice, France - (c) MEDPROJECT PHARMA, Bayern, Germany ⇒ Abstract #2010-160 Ocular Distribution and Spectrum of Activity of a Fully Human Anti-Herpes Simplex Virus IgG Fab Fragment, Following Topical Application BERDUGO-POLAK M (a,b), LARSEN IV (c), ABADIE C (d), KOWALCZUK L (a,b), TOUCHARD E (a,b), NELSON JD (e), ELENA PP (f), BRANDT CR (c), BEHAR-COHEN F (a,b,g), COMBETTE JM (d) ARVO meeting 2010; Fort Lauderdale, FL - USA. ARVO e-abstract No. 1991 - Poster D1028 (a) INSERM UMRS 872, Paris, France - (b) Pierre et Marie Curie University, Paris, France - (c) University of Wisconsin School of Medicine and Public Health, Madison, WI, USA - (d) RIBOVAX BIOTECHNOLOGIES, Petit-Lancy, Switzerland - (e) CALMUNE CORPORATION, San Diego, CA, USA - (f) IRIS PHARMA, Nice, France - (g) Hotel-Dieu University Hospital, Paris, France ⇒ Abstract #2009-154 Corneal Effect of Topical Diclofenac co-Administration with Aminoside and Steroid in Rabbits CAILLAUD T (a), VIAUD K (a), ELENA PP (a) ARVO meeting 2009; Fort Lauderdale, FL - USA. ARVO e-abstract No. 1957 (a) IRIS PHARMA, Nice, France ⇒ Poster #2008-149 Immunohistochemistry and in situ Zymography to Assess Matrix Metalloproteinases Expression and Activation by Latanoprost in Rat Uveoscleral Pathway ELENA PP (a), FRETON A (a), SPADAFORA A (a), GRILLO-ANTONELLI S (a), CIMBOLINI N (a), FERAILLE L (a), LAZDUNSKI M (b) ARVO meeting 2008; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 2008; 49: 2616. doi: (a) IRIS PHARMA, Nice, France - (b) IPMC-UMR 6097, Valbonne, France ⇒ Abstract #2007-148 Cationic oil-in-water emulsion as an improved cyclosporine ocular vehicle for vernal keratoconjuctivitis sicca (VKC) LAMBERT G (a), RABINOVICH-GUILATT L (a) ARVO meeting 2007; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 2007, Vol.48, 2301. doi: (collaboration) (a) NOVAGALI PHARMA SA, Evry, France ⇒ Abstract #2007-141 In vivo characterization of the anti-inflammatory effect of a multikinase inhibitor targeting angiogenesis and inflammation JENSEN L (a), HJARNAA P (a), FENSHOLDT J (a), ELENA PP (b), ABELL K (a), PETERSEN TK (a) 8th World Congress on Inflammation 2007; Copenhagen, Denmark. Inflamm Res. 2007; 56(suppl.3): S443, abstract P07.21 (a) LEO PHARMA, Ballerup, Denmark - (b) IRIS PHARMA, Nice, France ⇒ Abstract #2007-225 Ether-Lipid-Deficient-Mice Display Pigmentary Glaucoma Features as Well as Abnormal Retinal Vasculature ACAR N (a), SICARD P (b), SCHNEBELEN C (a), CIMBOLINI N (c), IVINGS L (a), GRILLO-ANTONELLI S (c), ROCHETTE L (b), CREUZOT-GARCHER CP (a,d), BRETILLON L (a), JUST WW (e) ARVO meeting 2007; Fort Lauderdale, FL - USA. Investigative Ophthalmology & Visual Science May 2007, Vol.48, 2978. doi: (a) INRA, Dijon, France - (b) Faculties of Medicine and Pharmacy, Dijon, France - (c) IRIS PHARMA, Nice, France - (d) University Hospital, Dijon, France - (e) Biochemie Zentrum Heidelberg (BZH), Heidelberg, Germany #2006-128 Effects of Dexamethasone in a Rat model of choroidal neovascularization FERAILLE L (a), GRILLO-ANTONELLI S (a), CIMBOLINI N (a), CAILLAUD T (a), ELENA PP (a) Ocular Anti-Angiogenesis meeting 2006; London - United Kingdom (a) IRIS PHARMA, Nice, France ⇒ Poster #2005-127 Variation of Krüppel-like factors levels in mouse corneal model of angiogenesis CHIAMBARETTA F, DE GRAEVE F, FERAILLE L, NEZZAR H, MARCEAU G, DASTUGNE B, RIGAL D, ELENA PP, SAPIN V ARVO meeting 2005; Fort Lauderdale, FL. Invest. Ophthalmol. Vis. Sci. 2005; 46: ARVO e-abstract No. 2609 #2005-123 Variation of krüppel-like factors ARNm levels in a mouse corneal model of angiogenesis CHIAMBARETTA F, NEZZAR H, FERAILLE L, DE GRAEVE F, MARCEAU G, ELENA PP, RIGAL D, DASTUGUE B, SAPIN V SFO meeting 2005; Paris – France. Abstract No. 380 #2004-116 PKC412 content in retina, choroid and plasma of pup mice with retinal neovascularization induced by hypoxic stimuli ELENA PP (a), AMAR T (a), CAILLAUD T(a), WONG M (b), BIZEC JC (c) ARVO meeting 2004; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 2004; 45: ARVO e-abstract No. 4053 (a) IRIS PHARMA, Nice, France - (b) NOVARTIS PHARMA, East Hanover, USA - (C) NOVARTIS PHARMA AG, Basel, Switzerland ⇒ Abstract #2004-115 PKC412 reduces retinal neovascularization induced by hypoxic stimuli in pup mice CAILLAUD T (a), AMAR T (a), OTTLECZ A (b), WONG M (c), LAMBROU GN (b), ELENA PP (a) ARVO meeting 2004; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 2004; 45: ARVO e-abstract No. 4062 (a) IRIS PHARMA, Nice, France - (b) NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland - (c) NOVARTIS PHARMA, East Hanover, USA ⇒ Abstract #2002-113 Potency and duration of action of synthetic P2Y2 receptor agonists on Schirmer scores in rabbits YERXA BR (a), DOUGLASS JG (a), ELENA PP (b), CAILLAUD T (b), AMAR T (b), REDICK CC (a), PETERSON WM (a) Adv. Exp. Med. Biol. 2002; 506: 261-265 (a) Inspire Pharmaceuticals, Durham, USA - (b) IRIS PHARMA, Nice, France ⇒ Abstract #2001-110 Topical ocular instillation of nitric oxide synthase inhibitors and intraocular pressure in rabbits FLEISCHHAUER JC (a), LIU R (a), ELENA PP (b), FLAMMER J (a), HAEFLIGER IO (a) Klin. Monatsbl. Augenheidkd. 2001; 218: 351-353 (a) Laboratory of Ocular Pharmacology and Physiology, Basel, Switzerland - (b) IRIS PHARMA, Nice, France ⇒ Abstract #2001-108 Ocular distribution of CAT-152 after a single subconjunctival injection in a pigmented rabbit model of glaucoma filtration surgery ELENA PP, MCFARLANE S, GLOVER DR, AMAR T, CAILLAUD T ARVO meeting 2001; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 2001; 42: S544, abstract No. 2915 #2000-234 Effect of CO 2 pneumoperitoneum on early cellular markers of retinal ischemia in rabbits with a-chymotrypsin–induced glaucoma LENTSCHENE C (a), FREDJ-REYGROBELLET D (b), BOUAZIZ H (c), MAZOIT JX (d), NIESSEN F (a), BENHAMOU D (a) Surg. Endosc. 2000; 14: 1057–1961 DOI: 10.1007/s004640000257 (collaboration) (a) Hôpital Antoine Béclère, Clamart, France - (b) Faculté de Médecine Nice, France - (c) Hôpital Central, Nancy, France - (d) Hôpital de Bicêtre, le Kremlin Bicêtre Cedex, France #2000-104 Effect of SR121463, a selective non-peptide vasopressin V2 receptor antagonist, in a rabbit model of ocular hypertension LACHERETZ F, BARBIER A, SERRADEIL-LE GAL C, ELENA PP, MAFFRAND J, LE FUR G J. Ocul. Pharmacol. Ther. 2000; 16: 203-216 ⇒ Abstract #2000-103 Comparison of the effects of preserved and unpreserved formulations of timolol on the ocular surface of albino rabbits PISELLA PJ (a,b), FILLACIER K (d), ELENA PP (e), DEBBASCH C (b,c), BAUDOUIN C (a) Ophthalmic Res. 2000; 32: 3-8 (a) Department of Ophthalmology, Ambroise Paré Hospital, APHP, Paris, France - (b) Toxicology Laboratory, University of Paris-V René Descartes, Paris, France - (c) Department of Cellular Pharmacotoxicology, XV-XX Hospital, Paris, France - (d) Department of Ophthalmology, University of Nice, France - (e) IRIS PHARMA, Nice, France ⇒ Article #2000-101 Evaluation of a novel carteolol eye-drops with alginic acid as long action promoter TISSIE G, SEBASTIAN C, MAURIN F, SECHOY O, DRIOT JY, ELENA PP, TRINQUAND C EVER meeting 2000; Palma de Mallorca, Spain. Ophthalmic Res. 2000; 32(S2): 29, abstract No. 214 #2000-99 Potency and duration of action of synthetic P2Y2-receptor agonists on schirmer scores in rabbits YERXA BR, DOUGLASS JG, ELENA PP, CAILLAUD T, AMAR T, PETERSON WM (3rd International Conference on the Lacrimal Gland, Tear Film and Dry Eye Syndromes Maui, HI - USA) Cornea 2000; 19: S138 #1999-97 Benefits of a vasopressin V2 receptor antagonist, SR 121463, in the treatment of ocular hypertension in the rabbit SERRADEIL-LE GAL C, LACHERETZ F, BARBIER A, ELENA PP, PASCAL M, MAFFRAND JP, LE FUR G World Congress on Neurohypophysial Hormones. 1999; Edinburgh - UK #1999-96 INS365, a P2Y2 receptor agonist, increases Schirmer scores in albino rabbits YERXA BR, ELENA PP, CAILLAUD T, AMAR T, EVANS R ARVO meeting 1999; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1999; 40: S540, abstract No. 2848 #1998-95 Inflammation measurement and immunocharacterization of cell proliferation in an experimental model of proliferative vitreoretinopathy BAUDOUIN C, KHOSRAVI E, PISELLA PJ, ETTAICHE M, ELENA PP Ophthalmic Res. 1998; 30: 340-350 ⇒ Abstract #1998-94 The effect of pneumoperitoneum on intraocular pressure in rabbits with α-chymotrypsin-induced glaucoma LENTSCHENER C, LEVEQUE JP, MAZOIT JX, BENHAMOU D Anesth. Analg. 1998; 86: 1283-1288. (collaboration) #1998-93 Activity of SR121463, a selective non-peptide vasopressine V2 receptor antagonist, in a rabbit model of glaucoma LACHERETZ F, BARBIER A, SERRADEIL-LE GAL C, ELENA PP, MAFFRAND JP, LE FUR G (ISER 1998 Abstract No. 795; Paris - France) Exp. Eye Res. 1998; 67: S239 #1998-92 Protective effect of nicardipine, a calcium channel blocker on electroretinogram and retinal cytoskeletal damages after ischemia-reperfusion on the rat FREDJ-REYGROBELLET D, CAILLAUD T, ELENA PP ARVO meeting 1998; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1998; 39: S993, abstract No. 4591 #1998-91 Comparison of efficacy between ketotifen and olopatadine eyedrops in allergic conjunctivitis ELENA PP, AMAR T, FETZ A, SCHOCH C ARVO meeting 1998; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1998; 39: S549, abstract No. 2531 #1997-90 Ocular distribution of lomefloxacin 0.3 % after a single instillation in the infected eye of pigmented rabbits ELENA PP, JAUCH A J. Ocul. Pharmacol. Ther. 1997; 13: 551-558 ⇒ Abstract #1997-89 Intraocular pressure effects of topical rilmenidine in ocular hypertensive animals and in healthy volunteers and glaucoma subjects NORDMANN JP, ELENA PP, VILAIN C ISECOPP meeting 1997 Munich – Germany, p. 12 #1997-87 Analyse de l'inflammation et de la prolifération cellulaire intra-oculaires dans un modèle expérimental de prolifération vitréorétinienne PISELLA PJ, BECQUET F, ELENA PP, BAUDOUIN C Ophtalmologie (France) 1997; 11: 369-371 #1997-86 Effects of different formulations of mitoxantrone (solutions, nanospheres, liposomes) on glaucoma surgery in rabbits TILLEUL P, DENIS P, MAIGNEN F, ELENA PP, NORDMANN JP, LEVERGE R, ROSTENE W Ophthalmic Res. 1997; 29: 218-226 ⇒ Abstract #1997-85 Retinal damage and protection after ischemic injury in the rat: a reappraisal ELENA PP, CAILLAUD T, AMAR T, HARITON C ARVO meeting 1997; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1997; 38: S888, abstract No. 4151 #1997-83 Rilmenidine: effect on intraocular pressure in alpha-chymotrypsin rabbits AMAR T, NORDMANN JP, CASTAGNE I, VILAIN C, ELENA PP ARVO meeting 1997; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1997; 38: S814, abstract No. 3790 #1996-78 Histological and cytological retinal changes after pressure-induced ischemia in rat eye FREDJ-REYGROBELLET D, TABIASCO J, BALAS D, DENIS P, and ELENA PP (JERMOV 1996 Abstract No. 399; Montpellier - France) Vision Res. 1996; 36: S220 #1997-76 Protection induced by isopropyl unoprostone treatment after retinal ischemic injury in the rat MOREL MANDRINO P, CAILLAUD T, ELENA PP, HARITON C ARVO meeting 1997; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1997; 38: S103, abstract No. 502 #1996-81 Inflammation measurement and immunocharacterization of cell proliferation in experimental PVR BAUDOUIN C, PISELLA PJ, KHOSRAVI E, ETTAICHE M, ELENA PP ARVO meeting 1996; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1996; 37: S391, abstract No. 1808 #1996-77 Pharmacokinetics of 0.1 % azelastine eyedrops, a histamine-H1-antagonist, with or without an induced allergic conjunctivitis ELENA PP, KHOSRAVI E, BORBE H, HERBST M, PETER G ARVO meeting 1996; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1996; 37: S1027, abstract No. 4719 #1995-73 Allergic conjunctivitis and uveitis models: reappraisal with some marketed drugs KHOSRAVI E, ELENA PP, HARITON C Inflamm. Res. 1995; 44: 47-54 #1995-72 Intraocular pressure effects of topical renin inhibitor CGP 38560 in normal and ocular hypertensive animals and in healthy volunteers and glaucoma subjects NORDMANN JP, PERCICOT CL, ELENA PP, MATHIS GA ISECOPP meeting 1995; Geneva – Switzerland, p. 35 #1995-65 Dimethindene maleate in allergic conjunctivitis: a new indication for an old drug ELENA PP, KHOSRAVI E, HARITON C ARVO meeting 1995; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1995; 36: S1014, abstract No. 4699 #1994-61 Topical sodium sucrose octasulphate reduces corneal lesions in a keratoconjunctivitis sicca model in the rat CHIBRET H, ELENA PP, KHOSRAVI E, FREDJ-REYGROBELLET D ARVO meeting 1994; Sarasota, FL - USA. Invest. Ophthalmol. Vis. Sci. 1994; 35: 1693, abstract No. 2039 #1994-58 Angiotensin-II antagonists reduce intraocular pressure by a combined effect on aqueous humor synthesis and outflow MATHIS GA, PERCICOT C, MERMOUD A, ELENA PP ARVO meeting 1994; Sarasota, FL - USA. Invest. Ophthalmol. Vis. Sci. 1994; 35; 1483, abstract No. 1060 #1993-54 Mifepristone (RU 486): in vitro binding to glucocorticoid receptors in iris-ciliary body and in vivo effects on intraocular pressure in rabbits DENIS P, ELENA PP, NORDMANN JP, SARRIEAU A, SARAUX H, ROSTENE W ARVO meeting 1993; Sarasota, FL - USA. Invest. Ophthalmol. Vis. Sci. 1993; 34: 925, abstract No. 1115 #1986-11 Effects of a new anti-allergic agent: the magnesium salt of N-Acetyl-Aspartyl-Glutamic Acid on experimental allergic inflammation of the rabbit eye LAPALUS P, MOULIN G, BAYER V, FREDJ-REYGROBELLET D, ELENA PP Curr. Eye Res. 1986; 5: 517-522 #1986-9 Système alpha-adrenergique et pression intra-oculaire LAPALUS P, ELENA PP Rencontres Internationales de Chimie Thérapeutique, Clermont-Ferrand - France 1986 PRECLINICAL PHARMACOKINETICS #2017-213 Exploratory ocular surface distribution studies of azithromycin formulations based on semifluorinated alkanes FISCHER K (a), GRILLENBERGER R (a), AMAR T (b), KRÖSSER S (a) EVER meeting 2017; Nice, France. Acta Ophthalmologica. doi: 10.1111/j.1755-3768.2017.0S029 (a) NOVALIQ GmbH, 69120 Heidelberg, Germany - (b) IRIS PHARMA, La Gaude, France ⇒ Poster ⇒ Abstract #2017-212 Oral administration of the 11bhydroxysteroid-dehydrogenase type 1 inhibitor RO5093151 to patients with glaucoma: an adaptive, randomised, placebo-controlled clinical study SCHWAB D (a), STURM C (a), PORTRON A (a), FUERST-RECKTENWALD S (b), HAINZL D (c), JORDAN P (d), STEWART W (e), TEPEDINO M (f), DUBINER H (g) BMJ Open Ophth 2017;1:e000063. doi: 10.1136/bmjophth-2016-000063 (collaboration) (a) ROCHE INNOVATION CENTER, Clinical Pharmacology, Roche Pharmaceutical Research and Early Development, Basel, Switzerland - (b) ROCHE INNOVATION CENTER, Translational Medicine, Roche Pharmaceutical Research and Early Development,Basel, Switzerland - (c) ROCHE INNOVATION CENTER, Pharmaceutical Sciences, Roche Pharmaceutical Research and Early Development, Basel, Switzerland (d) Department of Biometrics, Product development, Roche Pharmaceutical Research and Early Development, Basel, Switzerland - (e) PRN Pharmaceutical Research Network, LLC, Cheyenne, Wyoming, USA - (f) Cornerstone Eye Care, Division of Health Care, High Point, North Carolina, USA - (g) Eye Care Centers Management, Inc., Clayton Eye Center, Morrow, Georgia, USA ⇒ Article #2017-206 Binding to ocular albumin as a half-life extension. Principle for intravitreally injected drugs: evidence from mechanistic rat and rabbit studies FUCHS H (a), IGNEY F (a) J. Ocul. Pharmacol. Ther. 2017; doi: 10.1089/jop.2016.0083 (collaboration) (a) BOEHRINGER INGELHEIM PHARMA GmbH & Co. KG, Biberach an der Riss, Germany #2014-185 Plasma and ocular pharmacokinetic study comparing 3 µL micro-drop to typical 40 µL drop volume of timolol 0.5% in pigmented rabbits VAN DER HEIDEN H (a,b), AMAR T (c), LICHTENAUEUR W (a) ARVO meeting 2014; Orlando, FL - USA. Invest. Ophthalmol. Vis. Sci. April 2014, Vol.55, 453. doi: (a) MU-DROP, Apeldoorn, Netherlands - (b) ZAMB, Hospital Pharmacy, Tilburg, Netherlands - (c) IRIS PHARMA, La Gaude, France ⇒ Abstract #2014-184 Ocular pharmacokinetic study comparing ramipril and ramiprilat formulations administered orally or topically in pigmented rabbits QUENTRIC Y (a), AMAR T (a), BARRE N (a), FERAILLE L (a), REKIK R (b) ARVO meeting 2014; Orlando, FL - USA. ARVO e-abstract No. 2360 - Poster B0036 (a) IRIS PHARMA, La Gaude, France - (b) OPHTHALMOLOGY CLINIC, Tunis, Tunisia ⇒ Abstract #2010-160 Ocular distribution and spectrum of activity of a fully human anti-herpes simplex virus IgG fab fragment, following topical application BERDUGO-POLAK M (a,b), LARSEN IV (c), ABADIE C (d), KOWALCZUK L (a,b), TOUCHARD E (a,b), NELSON JD (e), ELENA PP (f), BRANDT CR (c), BEHAR-COHEN F (a,b,g), COMBETTE JM (d) ARVO meeting 2010; Fort Lauderdale, FL - USA. ARVO e-abstract No. 1991 - Poster D1028 (a) INSERM UMRS 872, Paris, France - (b) Pierre et Marie Curie University, Paris, France - (c) University of Wisconsin School of Medicine and Public Health, Madison, WI, USA - (d) RIBOVAX BIOTECHNOLOGIES, Petit-Lancy, Switzerland - (e) CALMUNE CORPORATION, San Diego, CA, USA - (f) IRIS PHARMA, La Gaude, France - (g) Hotel-Dieu University Hospital, Paris, France ⇒ Abstract #2009-156 Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation AKPEK EK (a), VITTITOW J (b), VERHOEVEN RS (b), BRUBAKER K (b), AMAR T (c), POWELL KD (d), BOYER JL (b), CREAN C (b) J. Ocul. Pharmacol. Ther. 2009; 25: 433-439 (a) THE WILMER EYE INSTITUTE, Johns Hopkins Hospital, Baltimore, USA - (b) INSPIRE PHARMACEUTICALS, Durham, USA - (c) IRIS PHARMA, Nice, France - (d) ENTHALPY ANALYTICAL, Durham, USA ⇒ Abstract #2009-153 Snapshot test for investigating gels of anti-glaucoma compounds as topical formulations ELENA PP (a), POLLIN C (a), BERMON F (a), AMAR T (a), CAILLAUD T (a), POLZER H (b) ARVO meeting 2009; Fort Lauderdale, FL - USA. ARVO e-abstract No. 6002 (a) IRIS PHARMA, Nice, France - (b) MEDPROJECT PHARMA, Bayern, Germany ⇒ Abstract #2008-152 Ocular pharmacokinetic study following single and multiple azithromycin administrations in pigmented rabbits AMAR T (a), CAILLAUD T (a), ELENA PP (a) Curr Eye Res. 2008; 33: 149-158 (a) IRIS PHARMA, Nice, France ⇒ Abstract #2007-226 Netildex versus Tobradex®: ocular pharmacokinetic/pharmacodynamic after a single dose and after one-day treatment in pigmented rabbits CIVIALE C (a), BLANCO A (a), SUDANO-ROCCARO A (a), AMAR T (b), MAZZONE M (a) Invest. Ophthalmol. Vis. Sci. 2007; 48(13):4272. doi: (a) SIFI SPA, Lavinaio-Aci San Antonio, Italy - (b) IRIS PHARMA, Nice, France ⇒ Abstract #2006-131 Pharmacokinetics of clonidine after a single application of transscleral iontophoresis in rabbits CAILLAUD T (a), ROY P (b), VIAUD K (a), ELENA PP (a) ARVO meeting 2006; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 2006; 47: ARVO e-abstract No. 5109 (a) IRIS PHARMA, Nice, France - (b) EYEGATE, Paris, France #2006-130 Influence of solution composition and electrode design on transscleral iontophoresis delivery of dexamethasone disodium phosphate ROY P (a), VIAUD K (b), CAILLAUD T (b), ELENA PP (b) ARVO meeting 2006; Fort Lauderdale, FL - USA. ARVO e-abstract No. 5110 (a) EYEGATE, Paris, France - (b) IRIS PHARMA, Nice, France ⇒ Abstract #2004-116 PKC412 content in retina, choroid and plasma of pup mice with retinal neovascularization induced by hypoxic stimuli ELENA PP (a), AMAR T (a), CAILLAUD T (a), WONG M (b), BIZEC JC (c) ARVO meeting 2004; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 2004; 45: ARVO e-abstract No. 4053 (a) IRIS PHARMA, Nice, France - (b) NOVARTIS PHARMA, East Hanover, USA - (C) NOVARTIS PHARMA AG, Basel, Switzerland ⇒ Abstract #2002-111 Alginic acid effect on carteolol ocular pharmacokinetics in the pigmented rabbit TISSIE G (a), SEBASTIAN C (a), ELENA PP (b), DRIOT JY (a), TRINQUAND C (a) J. Ocul. Pharmacol. Ther. 2002; 18: 65-73 (a) LABORATOIRE BAUSCH & LOMB/CHAUVIN, Montpellier, France - (b) IRIS PHARMA, Nice, France ⇒ Abstract #2001-108 Ocular distribution of CAT-152 after a single subconjunctival injection in a pigmented rabbit model of glaucoma filtration surgery ELENA PP, MCFARLANE S, GLOVER DR, AMAR T, CAILLAUD T ARVO meeting 2001; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 2001; 42: S544, abstract No. 2915 #2000-102 Localisation of Venoruton in rat blood vessel after single oral administration SALLIN D, ELENA PP, ZIJLSTRA J 14th World Congress ot the 'Union Internationale de Phlebologie' Roma - Italy 2000 #2000-100 Alginic acid effect on ocular distribution of carteolol after a single instillation in pigmented rabbits SEBASTIAN C, TISSIE G, DRIOT JY, ELENA PP, TRINQUAND C EVER meeting 2000; Palma de Mallorca, Spain. Ophthalmic Res. 2000; 32(S2): 28, abstract No. 215 #1997-90 Ocular distribution of lomefloxacin 0.3 % after a single instillation in the infected eye of pigmented rabbits ELENA PP, JAUCH A J. Ocul. Pharmacol. Ther. 1997; 13: 551-558 ⇒ Abstract #1997-84 Ocular distribution of Rescula® Eye-Drops in the pigmented rabbit after a single topical administration CAILLAUD T, AMAR T, HARITON C, ELENA PP ARVO meeting 1997; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1997; 38: S815, abstract No. 3796 #1996-77 Pharmacokinetics of 0.1 % azelastine eyedrops, a histamine-H1-antagonist, with or without an induced allergic conjunctivitis ELENA PP, KHOSRAVI E, BORBE H, HERBST M, PETER G ARVO meeting 1996; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1996; 37: S1027, abstract No. 4719 #1996-74 Ocular bioavailability of ganciclovir gel, an anti-herpetic formulation, after topical administration to intact or removed corneal epithelium of rabbit eyes KHOSRAVI E, ELENA PP, GOLDSCHMIDT P, LUYCKX J ARVO meeting 1996; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1996; 37: S81, abstract No. 383 #1995-69 Lomefloxacin distribution after a single instillation in the infected eye of pigmented rabbits KHOSRAVI E, ELENA PP, JAUCH A ISECOPP meeting 1995 Geneva - Switzerland, p. 67 #1994-62 Ocular distribution of nicergoline after intravenous administration in rats ELENA PP, BERTHOLOM N, KHOSRAVI E JERMOV meeting 1994; Montpellier - France, p 173, abstract No. P12 #1994-60 Distribution of ganciclovir in the anterior uvea after topical application of 0.15 % ganciclovir gel to intact and HSV-infected eyes of rabbits ELENA PP, GOLDSCHMIDT P, CHAST F, SAUVAGEON H, LUYCKX J, KHOSRAVI E ARVO meeting 1994; Sarasota, FL - USA. Invest. Ophthalmol. Vis. Sci. 1994; 35: 1682, abstract No. 1984 #1993-55 Ocular pharmacokinetics of topically-applied ganciclovir in rabbits with intact or removed corneal epithelium CHIBRET H, ELENA PP, KHOSRAVI E ARVO meeting 1993; Sarasota, FL - USA. Invest. Ophthalmol. Vis. Sci. 1993; 34: 1050, abstract No. 1712 #1993-53 Piribédil: affinité pour les récepteurs dopaminergiques rétiniens et profil pharmacocinétique oculaire LAPALUS P (a), DENIS P (b), DRICI M (a), FREDJ-REYGROBELLET D (a), ELENA PP (c) J. Neur. 1993; 240 (Suppl 1): S17-S21 (a) School medicine, dep. pharmacology, Nice, France - (b) Hôpital Saint-Antoine, Paris, France - (c) IRIS PHARMA, Nice, France ⇒ Abstract #1992-52 Retinal dopaminergic receptor affinity and ocular pharmacokinetic profile of piribedil LAPALUS P, DENIS P, DRICI M, FREDJ-REYGROBELLET D, ELENA PP J. Neurol. 1992; 239 (Suppl 1): S17-S21 ⇒ Abstract #1992-51 Ocular pharmacokinetics of trimetazidine in the pigmented rat after a single oral administration ELENA PP, KHOSRAVI E, LAPALUS P, JOULIN Y, HARPEY C ISER meeting 1992; Stresa - Italy. Exp. Eye Res. 1992; 55: S55, abstract No. 184 #1992-49 Ocular pharmacokinetics of two preservatives, benzalkonium chloride or benzoxonium chloride, after instillation in the pigmented rabbit ELENA PP (a), KHOSRAVI E (a), LAPALUS P (b), ULRICH E (c) ISER meeting 1992; Stresa - Italy. Exp. Eye Res. 1992; 55: S54, abstract No. 182 (a) IRIS PHARMA, Nice, France - (b) School medicine, dep. pharmacology, Nice, France - (c) CIBA VISION, Switzerland #1992-48 Preclinical pharmacokinetics of the 14C-labelled aldose reductase inhibitor methosorbinil (E-0722) ELENA PP, KUNZ PA, LAPALUS P SOE meeting 1992, Brussels - Belgium. P. 188, abstract No. 737 #1990-37 Ocular pharmacokinetics of ganciclovir gel after a single administration LAPALUS P, ETTAICHE M, LUYCKX J, ELENA PP AER meeting 1990, Bad Honnef - Germany. P. 58, abstract No. 94 #1990-36 Hymecel pharmacokinetics after a single intracameral injection in phakic and aphakic eyes of pigmented rabbits ELENA PP, LAPALUS P, FREDJ-REYGROBELLET D, ETTAICHE M, ULRICH E AER meeting 1990, Bad Honnef - Germany. P. 25, abstract No. 6 #1990-32 Retinal dopaminergic receptors and distribution of piribedil LAPALUS P, ELENA PP, FREDJ-REYGROBELLET D, DENIS P ENS meeting 1990, Brighton - UK #1989-29 Pharmacokinetic and autoradiographic studies of basic fibroblast growth factor on de-epithelialized and intact rabbit eye FREDJ-REYGROBELLET D, ELENA PP, MOENNER M, BAUDOUIN C, ETTAICHE M, BARRITAULT D, LAPALUS P Curr. Eye Res. 1989; 8: 1141-1152 #1989-20 Pharmacokinetics of topically-administered aldose reductase inhibitor (E-0722) on pigmented rabbit eye LAPALUS P, FREDJ-REYGROBELLET D, ELENA PP AER meeting 1989, Montpellier - France. Doc. Ophthalmol. 1990; 76: 129-130, abstract No. 45 #1989-19 Pharmacokinetic and autoradiographic studies of basic fibroblast growth factor on de-epithelialised and intact rabbit eye FREDJ-REYGROBELLET D, ELENA PP, MOENNER M, BAUDOUIN C, ETTAICHE M, BARRITAULT D, LAPALUS P AER meeting 1989, Montpellier - France, Doc. Ophthalmol. 1990; 76: 111, abstract No. 13 #1984-3 Etude cinétique d'un anti-allergique, le 14C-T86 en instillation chez le lapin albinos LAPALUS P, MOULIN G, BAYER V, ELENA PP, NICOLAS C, LAPALUS F J. Biophys. Med. Nucl. 1984; 8: 195-198 #1984-2 Etude cinétique d'un anti-allergique, le 14C-T86, en instillation chez le lapin albinos LAPALUS P, MOULIN G, BAYER V, ELENA PP, NICOLAS C, LAPALUS F Congrès de Médecine Nucléaire de Langue Francaise; Nice - France 1984 OCULAR TOLERANCE & SAFETY #2018-215 Safety and Tolerability of Overdosed Artificial Tears by Abraded Rabbit Corneas DAULL P (a), RAYMOND E (b), FERAILLE L (b), GARRIGUE JS (a) J. Ocul. Pharmacol. Ther. 2018; doi: 10.1089/jop.2018.0040 (a) NOVAGALI Innovation Center, SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France ⇒ Article #2017-227 Ocular tolerance in rabbits after intracameral administration of a fixed combination of tropicamide, phenylephrine, and lidocaine with and without rinsing NUIJTS R (a), MENCUCCI R (b), VIAUD-QUENTRIC K (c), ELENA PP (c), OLMIERE C (d), BEHNDIG A (e) J. Cataract Refr. Surg. 2017; 43: 673-679. doi: 10.1016/j.jcrs.2017.03.025 (a) Maastricht Universitair Medisch Centrum, the Netherlands – (b) University of Florence, Italy – (c) IRIS PHARMA, La Gaude, France – (d) LABORATOIRES THEA, Clermont-Ferrand, France – (e) Umeå University, SWEDEN ⇒ Abstract #2017-207 Safety evaluation of cationic emulsions following refractive surgery procedures QUENTRIC Y (a), DAULL P (b), GROS E (a), ANTONELLI S (a), MAURO V (a), FERAILLE L (a), GARRIGUE JS (b) ARVO meeting 2017; Baltimore - USA. ARVO e-abstract No. 5297 - Poster B0250 (a) IRIS PHARMA, La Gaude, France - (b) NOVAGALI Innovation Center, SANTEN SAS, Evry, France ⇒ Poster #2016-202 Ocular tolerance in rabbits of intracameral administration of MYDRANE, a fixed combination of tropicamide, phenylephrine, and lidocaine for cataract surgery OLMIERE C (a), VIAUD K (b) EVER meeting 2016; Nice - France. (a) LABORATOIRES THEA, Clermont-Ferrand, France - (b) IRIS PHARMA, Nice, France ⇒ Abstract #2016-197 Long-term tolerance of preservative-free eye drops containing macrogol hydroxystearate as an excipient Tolérance à long terme d’un collyre sans conservateur contenant comme excipient du macrogol hydroxystearate VIAUD K (a), LEFRANC-JULLIEN S (a), FERAILLE L (a), ELENA PP (a) J. Fr. Ophtalmol. 2016; 39: 156-163; doi: 10.1016/j.jfo.2015.09.011 (a) IRIS PHARMA, Nice, France ⇒ Abstract #2015-189 In vivo ocular tolerance of a new preservative-free eye drop formulation in rabbits QUENTRIC Y (a), VIAUD K (a), LEFRANC-JULLIEN S (a), FERAILLE L (a), ELENA PP (a) ARVO meeting 2015; Denver, CO - USA. ARVO e-abstract No. 802 - Poster D0264 (a) IRIS PHARMA, Nice, France ⇒ Poster ⇒ Abstract #2014-183 Safety and tolerability of drugs within the suprachoroidal space in albino rabbits PATEL S (a), VERHOEVEN R (a), BURKE B (a), CACCIAMANI F (b), VIAUD-QUENTRIC K (b), EDELHAUSER H (c,a) ARVO meeting 2014; Orlando, FL - USA. ARVO e-abstract No. 4886 - Poster C0082 (a) CLEARSIDE BIOMEDICAL, Alpharetta, GA, USA - (b) IRIS PHARMA, Nice, France - (c) EMORY UNIV EYE CENTER, Atlanta, GA, USA ⇒ Abstract #2013-178 CLS suprachoroidal injectable suspension of triamcinolone acetonide is well tolerated in the albino rabbit VERHOEVEN R (a), VIAUD-QUENTRIC K (b), CACCIAMANI F (b), PATEL S (a) American College of toxicology 2013 San Antonio, Texas - USA. Poster P505 (a) CLEARSIDE BIOMEDICAL, Alpharetta, GA, USA - (b) IRIS PHARMA, Nice, France #2013-177 Suprachoroidal microinjection of triamcinolone acetonide is well tolerated in the albino rabbit VERHOEVEN R (a), PATEL S (a), VIAUD-QUENTRIC K (b), CACCIAMANI F (b), AMAR T (b), YERXA B (a) ARVO meeting 2013; Seattle, WA - USA. ARVO e-abstract No. 119 - Poster C0124 (a) CLEARSIDE BIOMEDICAL, Alpharetta, GA, USA - (b) IRIS PHARMA, Nice, France ⇒ Abstract #2009-154 Corneal effect of topical diclofenac co-administration with aminoside and steroid in rabbits CAILLAUD T (a), VIAUD K (a), ELENA PP (a) ARVO meeting 2009; Fort Lauderdale, FL - USA. ARVO e-abstract No. 1957 (a) IRIS PHARMA, Nice, France ⇒ Poster #2007-147 Ocular tolerability of iontophoresis ROY P (a), ELENA PP (b), VIAUD K (b), CAILLAUD T (b), CALIAS P (a) ARVO meeting 2007; Fort Lauderdale, FL - USA. ARVO e-abstract No. 5800 (a) EYEGATE PHARMACEUTICALS, Waltham, USA - (b) IRIS PHARMA, Nice, France #2006-129 Evaluation of ocular tolerability of repetitive corneal-scleral iontophoresis in pigmented rabbits ELENA PP (a), ROY P (b), VIAUD K (a), CAILLAUD T (a) ARVO meeting 2006; Fort Lauderdale, FL - USA. ARVO e-abstract No. 5094 (a) IRIS PHARMA, Nice, France - (b) EYEGATE, Paris, France #1995-66 Lack of cytotoxic effect of ganciclovir and acyclovir on rabbit corneal epithelial cells in vitro KHOSRAVI E, ELENA PP, GOLDSCHMIDT P, BAUDOUIN C, LUYCKX J JERMOV meeting 1995; Montpellier - France. Vision Res. 1995; 35: S173, abstract No. P125 #1990-38 Cytotoxicity studies in ophthalmology LAPALUS P, ETTAICHE M, FREDJ-REYGROBELLET D, JAMBOU D, ELENA PP Lens Eye Toxic Res. 1990; 7: 231-242 CLINICAL RESEARCH #2020-228 Topical low dose preservative-free hydrocortisone reduces signs and symptoms in patients with chronic dry eye: a randomized clinical trial KALLAB M (a), SZEGEDI S (a), HOMMER N (a), STEGMANN H (a), KAYA S (b), WERKMEISTER RM (a), SCHMIDL D (a), SCHMETTERER L (a)(c)(d)(e), GARHÖFER G (a) Adv. Ther. 2020; 37: 329–341 doi: 10.1007/s12325-019-01137-8 (collaboration) (a) Medical University of Vienna, Vienna, Austria - (b) Department of Ophthalmology, Hietzing Hospital, Vienna, Austria - (c) Singapore Eye Research Institute, Singapore, Singapore - (d) Nanyang Technological University, Singapore, Singapore - (e) Ophthalmology and Visual Sciences Academic Clinical Program, Duke-NUS Medical School, Singapore, Singapore ⇒ Article #2018-217 Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study ECONOMOU M (a), KOLSTAD LAUKELAND H (b,c), GRABSKA-LIBEREK I (d), ROULAND JF (e) Clinical Ophthalmol. 2018; 12: 2399–2407 (collaboration) (a) St Erik’s Eye Hospital, Stockholm, Sweden - (b) University Hospital, Trondheim, Norway - (c) Norwegian University of Science and Technology, Trondheim, Norway - (d) Ophthalmology Clinic Postgraduate Centre of Medical Education, Warszawa, Poland - (e) Claude Huriez Hospital, Lille, France ⇒ Article #2010-159 Dry Eye Syndrome : the regulatory challenge. Clinical trial and regulatory challenges faced by Iris Pharma in the development of dry eye therapies QUENTRIC Y (a) TFOS Global Dry Eye Experts' meeting 2010; Florence - Italy. Oral Communication (a) IRIS PHARMA, Nice, France #2009-155 Associer les patients atteints de DMLA à la recherche, est-ce possible? BENCHABOUNE M (a) Vu et Entendu. 2009; 2: 4 (a) IRIS PHARMA, Nice, France ⇒ Article #2008-151 Tear concentrations of azithromycin following topical administration of a single dose of azithromycin 0.5%, 1.0%, and 1.5% eyedrops (T1225) in healthy volunteers CHIAMBARETTA F, GARRAFFO R, ELENA PP, POULIQUEN P, DELVAL L, RIGAL D, DUBRAY C, GOLDSCHMIDT P, TABBARA K, COCHEREAU I Eur. J. Ophthalmol. 2008; 18(1): 13-20 ⇒ Abstract #2007-144 Trend of prescription of silicon hydrogel lens by ophthalmologists and lens assessment by patients CROS BOIDEVEZI M (a), STEVE L (a), JOUVENCEL R (a), CLIROPHTHA (b) 29th IEEE EMBS Annual International Conference 2007; Lyon - France (a) CIBA VISION France, Paris, France - (b) CLIROPHTHA, Nice, France #2007-143 A new method for intra ocular pressure in vivo measurement: first clinical trials DUBOIS P, ZEMMOURI J, ROULAND JF, ELENA PP, LOPES R, PUECH P 29th IEEE EMBS Annual International Conference 2007; Lyon - France Conf Proc IEEE Eng Med Biol Soc. 2007;2007:5763-5766. doi:10.1109/IEMBS.2007.4353656 ⇒ Article ⇒ Abstract #2006-139 Improvement of dry eye symptoms with polyunsaturated fatty acids GARCHER C, PASSEMARD M, LAFONTAINE PO, VIAU S, JOFFRE C, ELENA PP, POULIQUEN P, BAUDOUIN C, BRON AM Acta Ophthalmologica Scandinavica. 2006; 84 Supplement 239: 135 #2006-138 Amélioration de la symptomatologie chez des patients atteints de sécheresse oculaire et traités oralement par des acides gras polyinsaturés. Improvement of dry eye symptoms with polyunsaturated fatty acids GARCHER C, PASSEMARD M, VIAU S, JOFFRE C, LAFONTAINE PO, ELENA PP, POULIQUEN P, BAUDOUIN C, BRON AM SFO meeting 2006; Paris - France (Oral communication No. 220) #2006-137 Enquête prospective, nationale, multicentrique auprès de 345 patients anciens et nouveaux porteurs sur la santé oculaire, la performance visuelle et la satisfaction des lentilles 02 OPTIX TORIC DELFOUR-MALECAZE M (a), STEVE L (b), CLIROPHTHA (c) Réflexions Ophtalmol. 2006; 95: 50-53 (a) Toulouse, France (b) CIBA VISION France, Paris, France - (c) CLIROPHTHA, Nice, France #2006-136 Improvement of dry eye symptoms with polyunsaturated fatty acids CREUZOT C, PASSEMARD M, VIAU S, JOFFRE C, POULIQUEN P, ELENA PP, BRON A, BRIGNOLE F J. Fr. Ophtalmol. 2006; 29(8): 868-73 ⇒ Article #2006-135 Trend of prescription of silicone hydrogel lens by ophthalmologists and lens assessment by patients CROS BOIDEVEZI M (a), STEVE L (a), JOUVENCEL R (a), CLIROPHTHA (b) 36th ECLSO Congress 2006; Dubrovnik - Czech Republic. Abstract No. 9 (a) CIBA VISION France, Paris, France - (b) CLIROPHTHA, Nice, France #2006-134 Etude comparative des implants Alcon asphériques (SN60WF) versus standards (SN60AT) MONTARD M Safir meeting 2006. Paris - France (collaboration) #2006-133 Improvement of dry eye symptoms with polyunsaturated fatty acids GARCHER C (a), PASSEMARD M (a), LAFONTAINE PO (a), VIAU S (b), JOFFRE C (b), ELENA PP (c), POULIQUEN P (d), BAUDOUIN C (e), BRON AM (a) EVER meeting 2006; Vilamoura - Portugal. Free paper No. 3155 and poster No. 335 (a) Hopital General, Dijon, France - (b) INRA - Eye and Nutrition Unit, Dijon, France (c) CLIROPHTHA, Nice, France (d) LABORATOIRES THEA, Clermont-Ferrand, France - (e) CHNO XV-XX, Paris, France ⇒ Abstract #2006-132 Improvement of dry eye symptoms with polyunsaturated fatty acids GARCHER C, PASSEMARD M, LAFONTAINE PO, VIAU S, JOFFRE C, ELENA PP, POULIQUEN P, BAUDOUIN C, BRON AM ARVO meeting 2006; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 2006; 47: ARVO e-abstract No. 236 ⇒ Abstract #2005-126 Regard® : une enquête sur la tolérance et le confort oculaire d'une solution d'entretien pour lentilles de contact sans conservateur MALET F, CLIROPHTHA Réflexions Ophtalmol. 2005; 84: 62-65 #2005-125 Une nouvelle méthode de mesure de la pression intraoculaire DUBOIS P (a), ZEMMOURI J (b), ROULAND JF (c), ELENA PP (d) IRBM 26; 4: 285-290 (a) Institut de technologie médicale, CHRU, Lille, France - (b) Laboratoire de spectroscopie hertzienne, USTL, Villeneuve d’Ascq, France - (c) Hôpital Huriez, Lille, France - (d) IRIS PHARMA, Nice, France ⇒ Abstract #2005-124 Comparison of carteolol plasmatic levels after repeated instillations of long-acting and regular formulations of carteolol 2% in glaucoma patients RENARD P (a), KOVALSKI JL (b), COCHEREAU I (c), JAULERRY S (d), WILLIAMSON W (e), ELENA PP (f), LABLACHE COMBIER M (g), ALLAIRE C (g), SIOU-MERMET R (g) Graefe's Arch. Clin. and Exp. Ophthalmol. 2005; 243: 1221-1227 (a) Institut Vernes, Paris, France - (b) HIA Clermont Tonnerre, Brest, France - (c) CHRU, Angers, France - (d) CH Tarbes Vic Bigorre, Tarbes, France - (e) CH François Mitterrand, Pau, France - (f) IRIS PHARMA-CLIROPHTHA, Nice, France - (g) BAUSCH & LOMB, Paris, France ⇒ Abstract #2004-203 Efficacy and safety of three ophthalmic inserts for topical anaesthesia of the cornea. An exploratory comparative dose-ranging, double-blind, randomized trial in healthy volunteers MAHE I (a), MOULY S (a), JARRIN I (a), OTERO J (a), TAVERA C (b), SIMONEAU G (c), TILLET Y (c), CONTI R (b), EL MESKI S (b), GAUDRIC A (a), JF BERGMANN (a) Br. J. Clin. Pharmacol. 2004; 59:2 220 – 226 (collaboration) (a) Hôpital Lariboisière, Paris, France - (b) IOLTECH, La Rochelle, France - (c) WHITE-TILLET Consultants, Chelles, France ⇒ Article #2004-122 Ocular hypotensive effect of a new “once-daily” eye-dops formulation of 0.5% timolol (Timolast™) in comparison to Timoptol® 0.5% administered twice-daily ROULAND JF (a), MOREL-MANDRINO P (b), ELENA PP (b), DE GREGORIO F (c), BAROZZI C (c), FEDELI E (c), FERREIRA VD (c) ISOPT meeting 2004; Monte-Carlo – Monaco (a) Hôpital Huriez, Lille, France - (b) CLIROPHTHA, Nice, France - (c) TUBILUX PHARMA SpA, Roma, Italy #2004-121 Intérêt d’une nouvelle formulation de diclofénac sans conservateur pour la surface oculaire CHIAMBARETTA F (a), CREUZOT-GARCHER C (b), PILON F (a), POULIQUEN P (c), REBIKA H (c), DUBRAY C (d), RIGAL D (a) J. Fr. Ophtalmol. 2004; 27, 7, 739-744 (collaboration) (a) Hôpital Gabriel Montpied, Clermont-Ferrand, France - (b) CHU de Dijon, Dijon, France - (C) LABORATOIRES THEA, Clermont-Ferrand, France - (d) Unité de Pharmacologie Clinique, Centre de Recherche en Nutrition Humaine, Clermont-Ferrand, France ⇒ Article #2004-120 Comparison of once-daily nonpreserved timolol and timolol maleate gel-forming solution associated with latanoprost BRON A, VELASQUE L, REBICA H, POULIQUEN P, ELENA PP, ROULAND JF J. Fr. Ophtalmol. 2004; 27(9 Pt 1): 971-7 ⇒ Abstract #2004-119 Non-inferiority, in the intra-ocular pressure (IOP)-lowering effect, of a new eye-drops formulation of 0.5% timolol (Timolast™) instilled once-daily versus 0.5% Timoptol®, instilled twice-daily, for 4 months in ocular hypertensive or glaucomatous patients ROULAND JF (a), MOREL-MANDRINO P (b), DE GREGORIO F (c), BAROZZI C (c), FEDELI E (c) ARVO meeting 2004; Fort Lauderdale, FL – USA. Invest. Ophthalmol. Vis. Sci. 2004; 45(13): 2080. doi: (a) Hôpital Huriez, Lille, France - (b) CLIROPHTHA, Nice, France - (c) TUBILUX PHARMA SpA, Roma, Italy ⇒ Abstract #2004-118 Comparison of carteolol plasmatic levels after repeated instillations of long acting and regular formulations of carteolol 2% in glaucomatous patients ALLAIRE CM (a) , RENARD P (b) , KOVALSKI J (c) , COCHEREAU I (d) , JAULERRY S (e) , WILLIAMSON W (f) , ELENA PP (g), LABLACHE-COMBIER M (a) ARVO meeting 2004; Fort Lauderdale, FL – USA. Invest. Ophthalmol. Vis. Sci. 2004; 45: ARVO e-abstract No. 957 (a) BAUSCH & LOMB, Paris, France - (b) Institut Vernes, Paris, France - (c) HIA Clermont Tonnerre, Brest, France - (d) CHRU, Angers, France - (e) CH Tarbes Vic Bigorre, Tarbes, France - (f) CH François Mitterrand, Pau, France - (g) IRIS PHARMA-CLIROPHTHA, Nice, France ⇒ Abstract #2004-117 Efficacy and safety of diclofenac 0.1% ABAK® versus preserved diclofenac® 0.1% eye drops in controlling post-cataract surgery inflammation GOLDSCHMIDT P, ELENA PP, BALDWIN H, DELVAL L, COLIN J ARVO meeting 2004; Fort Lauderdale, FL – USA. Invest. Ophthalmol. Vis. Sci. 2004; 45: ARVO e-abstract No. 294 ⇒ Abstract #2002-112 Timolol 0.1% Gel (Nyogel 0.1%®) Once Daily versus Conventional Timolol 0.5% Solution Twice Daily: A Comparison of Efficacy and Safety ROULAND JF (a), MOREL-MANDRINO P (b), ELENA PP (b), POLZER H (c), SUNDER RAJ P (d) Ophthalmologica 2002; 216: 449-454 (a) Hôpital Huriez, Lille, France - (b) CLIROPHTHA, Nice, France - (c) MEDPROJECT PHARMA, Sauerlach, Germany - (d) NOVARTIS OPHTHALMICS, Farnborough, UK ⇒ Abstract #2001-109 A Novel Once-a-Day Timolol 0.1% Gel Formulation has an equivalent IOP-lowering efficacy to timolol 0.5% solution ROULAND JF (a), MOREL-MANDRINO P (b), ELENA PP (b), POLZER H (c) IGS meeting 2001; Prague - Czech Republic (a) Hôpital Huriez, Lille, France - (b) CLIROPHTHA, Nice, France - (c) MEDPROJECT PHARMA, Sauerlach, Germany #2000-106 A new long acting ophthalmic formulation of carteolol containing alginic acid SECHOY O (a), TISSIE G (a), SEBASTIAN C (a), MAURIN F (a), DRIOT JY (a), TRINQUANT C (a) Int. J. Pharm. 2000; 207: 109-116 (collaboration) (a) LABORATOIRE CHAUVIN, Montpellier, France ⇒ Abstract #2000-105 Therapeutic equivalence of a timolol 0.1% hydrogel (T-Gel 0.1%) QD and aqueous timolol 0.5% BID in reducting the IOP of glaucomatous patients ELENA PP, ROULAND JF, MOREL-MANDRINO P, POLZER H ARVO meeting 2000; Fort Lauderdale, FL – USA. Invest. Ophthalmol. Vis. Sci. 2000; 41: S281, abstract No. 2477 #1998-233 Klinische und pharmakokinetische Untersuchungen zur perioperativen antiphlogistischen Wirksamkeit von Prednisolon-Gel bei der Kataraktextraktion STRUKE HG, STOLDT G Ohrloff C., Kohnen T., Duncker G. (eds) 11. Kongreß der Deutschsprachigen Gesellschaft für Intraokularlinsen-Implantation und refraktive Chirurgie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-71952-3_60 (collaboration) #1997-89 Intraocular pressure effects of topical rilmenidine in ocular hypertensive animals and in healthy volunteers and glaucoma subjects NORDMANN JP, ELENA PP, VILAIN C ISECOPP meeting 1997 Munich – Germany, p. 12 #1997-88 Efficacy and local ocular tolerance of Rescula eye drops in glaucoma patients NORDMANN JP, ROULAND JF, ELENA PP, KAPOK B ISECOPP meeting 1997 Munich – Germany, p. 27 #1997-82 Rilmenidine: safety and efficacy on intraocular pressure in healthy volunteers and glaucoma patients NORDMANN JP, ELENA PP, MOREL-MANDRINO P, CASTAGNE I, VILAIN C ARVO meeting 1997; Fort Lauderdale, FL – USA. Invest. Ophthalmol. Vis. Sci. 1997;38 : S559, abstract No. 2600 #1996-75 Assessment of the safety and local pharmacokinetics of 0.15 % gel of ganciclovir (Virgan®) in healthy volunteers POULIQUEN P (a), ELENA PP (b), MALECAZE F (c), LUYCKX J (a), LANOUE A (a), GOLDSCHMIDT P (d) ARVO meeting 1996; Fort Lauderdale, FL – USA. Invest. Ophthalmol. Vis. Sci. 1996; 37: S313, abstract No. 1431 (a) LABORATOIRES THEA, Clermont-Ferrand, France - (b) CLIROPHTHA, Nice, France - (c) Hôpital Purpan, Toulouse, France - (d) Centre Hospitalier Universitaire de la Pitié-Salpêtrière, Paris, France #1995-72 Intraocular pressure effects of topical renin inhibitor CGP 38560 in normal and ocular hypertensive animals and in healthy volunteers and glaucoma subjects NORDMANN JP, PERCICOT CL, ELENA PP, MATHIS GA ISECOPP meeting 1995; Geneva – Switzerland, p. 35 #1995-71 One drop study to evaluate safety and efficacy of SR43845, a renin inhibitor, in healthy volunteers DENIS P, NORDMANN JP, ELENA PP, JAILLON P, MATHIS G, SARAUX H ARVO meeting 1995, Fort Lauderdale, FL – USA. Invest. Ophthalmol. Vis. Sci. 1995; 36: S734, abstract No. 3388 #1995-70 Evaluation of safety and efficacy of CGP38560, a renin inhibitor, in healthy volunteers and glaucoma subjects NORDMANN JP, DENIS P, ELENA PP, MATHIS GA, SCHNARR KD, TETZLOFF W, KERKMANN T ARVO meeting 1995, Fort Lauderdale, FL – USA. Invest. Ophthalmol. Vis. Sci. 1995; 36: S719, abstract No. 3317 #1994-59 Central nervous system control of intraocular pressure DENIS P (a), NORDMANN JP (a), ELENA PP (b), SARAUX H (a), LAPALUS P (c) Fundam. Clin. Pharmacol. (France) 1994; 8 : 230-237 (a) Hôpital Saint-Antoine, dep. ophthalmology, Paris, France - (b) IRIS PHARMA, Nice, France - (c) School medicine, dep. pharmacology, Nice, France DEVICES & EVALUATIONS #2014-182 Biocompatibility of MedinGel biodegradable drug delivery system in the eye SPIS M (a), FERAILLE L (b), ANTONELLI S (b), CIMBOLINI N (b), ELENA PP (b), GAUDRIAULT G (a), PETIT A (a) Invest. Ophthalmol. Vis. Sci. 2014;55(13):5273. (a) MEDINCELL, Jacou, France - (b) IRIS PHARMA, Nice, France ⇒ Abstract #2014-185 Plasma and ocular pharmacokinetic study comparing 3 µL micro-drop to typical 40 µL drop volume of timolol 0.5% in pigmented rabbits VAN DER HEIDEN H (a,b), AMAR T (c), LICHTENAUEUR W (a) Invest. Ophthalmol. Vis. Sci. 2014; 014;55(13):453. (a) MU-DROP, Apeldoorn, Netherlands - (b) ZAMB, Hospital Pharmacy, Tilburg, Netherlands - (c) IRIS PHARMA, Nice, France ⇒ Abstract #2012-174 Assessment of a new device for conjunctival impression ROY P (a), CIMBOLINI N (b), ANTONELLI S (b), FERAILLE L (b), ELENA PP (b), BAUDOUIN C (c) MCLOSA meeting 2012; London - England (a) OPIA TECHNOLOGIES, Paris, France - (b) IRIS PHARMA, Nice, France - (c) Ophthalmology, Quinze-Vingts Hospital, Paris, France #2012-166 Assessment of a new device for conjunctival impression ROY P (a), CIMBOLINI N (b), ANTONELLI S (b), FERAILLE L (b), ELENA PP (b), BAUDOUIN C (c) Invest. Ophthalmol. Vis. Sci. 2012;53(14):1868. (a) OPIA TECHNOLOGIES, Paris, France - (b) IRIS PHARMA, Nice, France - (c) Ophthalmology, Quinze-Vingts Hospital, Paris, France ⇒ Abstract #2011-165 Assessment of a new device for conjunctival impression ROY P (a), CIMBOLINI N (b), ANTONELLI S (b), FERAILLE L (b), ELENA PP (b) Oral presentation. ISOPT meeting 2011; Vienna, Austria (a) OPIA TECHNOLOGIES, Paris, France - (b) IRIS PHARMA, Nice, France #2011-164 Explorations et imagerie rétinienne BENCHABOUNE M (a) STO meeting 2011; Tunis - Tunisia (Oral Communication in French) (a) IRIS PHARMA, Nice, France #2011-163 Adaptative optics imaging in age-related macular degeneration GOCHO-NAKASHIMA K (a), BENCHABOUNE M (b), ULLERN M (a), LAMORY B (c), CHATEAU N (c), SAHEL JA (a), PAQUES M (a) EVER meeting 2011; Crete - Greece (Oral Communication) (a) INSERM 503, Paris, France - (b) IRIS PHARMA, Nice, France - (c) IMAGINE EYES, Orsay, France ⇒ Abstract #2011-162 In vivo microscopic imaging of drusen using adaptive optics LAMORY B (a), NAKASHIMA K (b), BENCHABOUNE M (b,c), ULLERN M (b), VUAILLAT E (a), SAHEL JA (b), PAQUES M (b) ARVO meeting 2011; Fort Lauderdale, FL - USA. ARVO e-abstract No. 4469/A218 (a) IMAGINE EYES, Orsay, France - (b) INSERM 503, Paris, France - (c) IRIS PHARMA, Nice, France ⇒ Abstract #2011-161 Evaluation of membrane material for impression cytology ROY P (a), CIMBOLINI N (b), FERAILLE L (b), KECHAD M (b), ELENA PP (b) ARVO meeting 2011; Fort Lauderdale, FL - USA. ARVO e-abstract No. 1937 - Poster D918 (a) OPIA TECHNOLOGIES, Paris, France - (b) IRIS PHARMA, Nice, France ⇒ Abstract #2007-147 Ocular tolerability of iontophoresis ROY P (a), ELENA PP (b), VIAUD K (b), CAILLAUD T (b), CALIAS P (a) Invest. Ophthalmol. Vis. Sci. 2007;48(13):5800. (a) EYEGATE PHARMACEUTICALS, Waltham, USA - (b) IRIS PHARMA, Nice, France ⇒ Abstract #2007-146 New evaluation techniques in ocular surface diseases : comparison of antiallergic drugs using in vivo confocal microscopy for assessing late response of induced ocular anaphylaxis in the guinea pig FERAILLE L (a) Oral presentation. EVER meeting 2007; Portoroz, Slovenia (a) IRIS PHARMA, Nice, France #2007-145 Update on drug delivery systems used in the anterior part of the eye : review of the new drug delivery systems for the anterior chamber ELENA PP (a) Oral presentation. ESCRS meeting 2007; Stockholm, Sweden (a) IRIS PHARMA, Nice, France #2007-144 Trend of prescription of silicon hydrogel lens by ophthalomologists and lens assessment by patients CROS BOIDEVEZI M (a), STEVE L (a), JOUVENCEL R (a), CLIROPHTHA (b) 29th IEEE EMBS Annual International Conference 2007; Lyon - France (a) CIBA VISION France, Paris, France - (b) CLIROPHTHA, Nice, France #2007-143 A new method for intra ocular pressure in vivo measurement: first clinical trials DUBOIS P (a), ZEMMOURI J (b), ROULAND JF (c), ELENA PP (d), LOPES R (a), PUECH P (a) 29th IEEE EMBS Annual International Conference 2007; Lyon - France doi: 10.1109/IEMBS.2007.4353656 (a) INSERM 703, Lille, France - (b) Laboratoire de Spectroscopie Hertzienne, Lille, France - (c) Ophthalmology, Quinze-Vingts Hospital, Paris, France - (d) IRIS PHARMA, Nice, France ⇒ Abstract #2006-137 Enquête prospective, nationale, multicentrique auprès de 345 patients anciens et nouveaux porteurs sur la santé oculaire, la performance visuelle et la satisfaction des lentilles 02 OPTIX TORIC DELFOUR-MALECAZE M (a), STEVE L (b), CLIROPHTHA (c) Réflexions Ophtalmol. 2006; 95: 50-53 (a) Toulouse, France (b) CIBA VISION France, Paris, France - (c) CLIROPHTHA, Nice, France #2006-135 Trend of prescription of silicone hydrogel lens by ophthalmologists and lens assessment by patients CROS BOIDEVEZI M (a), STEVE L (a), JOUVENCEL R (a), CLIROPHTHA (b) 36th ECLSO Congress 2006; Dubrovnik - Czech Republic. Abstract No. 9 (a) CIBA VISION France, Paris, France - (b) CLIROPHTHA, Nice, France #2006-134 Etude comparative des implants Alcon asphériques (SN60WF) versus standards (SN60AT) MONTARD M Safir meeting 2006. Paris - France (collaboration). #2006-131 Pharmacokinetics of clonidine after a single application of transscleral iontophoresis in rabbits CAILLAUD T (a), ROY P (b), VIAUD K (a), ELENA PP (a) ARVO meeting 2006; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 2006; 47: ARVO e-abstract No. 5109 (a) IRIS PHARMA, Nice, France - (b) EYEGATE, Paris, France #2006-130 Influence of solution composition and electrode design on transscleral iontophoresis delivery of dexamethasone disodium phosphate ROY P (a), VIAUD K (b), CAILLAUD T (b), ELENA PP (b) Invest. Ophthalmol. Vis. Sci. 2006;47(13):5110 (a) EYEGATE, Paris, France - (b) IRIS PHARMA, Nice, France ⇒ Abstract #2006-129 Evaluation of ocular tolerability of repetitive corneal-scleral iontophoresis in pigmented rabbits ELENA PP (a), ROY P (b), VIAUD K (a), CAILLAUD T (a) ARVO meeting 2006; Fort Lauderdale, FL - USA. ARVO e-abstract No. 5094 (a) IRIS PHARMA, Nice, France - (b) EYEGATE, Paris, France #2005-125 Une nouvelle méthode de mesure de la pression intraoculaire DUBOIS P (a), ZEMMOURI J (b), ROULAND JF (c), ELENA PP (d) IRBM 26; 4: 285-290 - doi:10.1016/j.rbmret.2005.04.013 (a) Institut de technologie médicale, CHRU, Lille, France - (b) Laboratoire de spectroscopie hertzienne, USTL, Villeneuve d’Ascq, France - (c) Hôpital Huriez, Lille, France - (d) IRIS PHARMA, Nice, France ⇒ Abstract #1995-68 Non-invasive measurement of ocular temperature by using infrared thermographic analysis in immune and non-immune allergy models ELENA PP, KHOSRAVI E, HARITON C ISECOPP meeting 1995 Geneva - Switzerland, p. 60 #1991-47 La radioautographie en ophtalmologie: méthodologie et applications à l'étude des récepteurs oculaires et à l'hybridation in situ DENIS P, ELENA PP, NORDMANN JP, DUSSAILLANT M, LAPALUS P, SARAUX H, ROSTENE W "Physiologie, Pathologie et Génétique Oculaire." CHRISTEN Y AND DROIX-LEFAIX MT ed. (Springer Verlag, Paris, 1991), 105-113 #1990-34 Localization and characterization of receptors in human and animal eyes by “ in vitro ” autoradiography ELENA PP, DENIS P, FREDJ-REYGROBELLET D, ROSTENE W, LAPALUS P ISER meeting 1990; Helsinki - Finland, p 228, abstract No. 803 FORMULATION & DRUG DELIVERY #2021-239 Review of Preclinical Outcomes of a Topical Cationic Emulsion of Cyclosporine A for the Treatment of Ocular Surface Diseases DAULL P (a), BAUDOUIN C (b), LIANG H (c), FERAILLE L (d), BARABINO S (e), GARRIGUE JS (a) Ocul. Immunol. Inflamm. 2021. Aug 4;1-11 doi: 10.1080/09273948.2021.1957124 (a) SANTEN SAS, Evry, France - (b) CHNO des Quinze-Vingts, IHU FOReSIGHT, INSERM-DGOS CIC 1423, Paris, France - (c) Sorbonne Universités, INSERM, CNRS, Institut de la Vision, Paris, France - (d) IRIS PHARMA, La Gaude, France - (e) OCULAR SURFACE & DRY EYE CENTER, University of Milan, Italy ⇒ Article #2021-236 Ocular surface response of two preservative-free cylcosporine A emulsion eye drops in a mouse model of dry eye DAULL P (a), NAGANO T (b), GROS E (c), FERAILLE L (c), BARABINO S (d), GARRIGUE JS (a) Curr. Eye Res. 2021 Jan 15. doi: 10.1080/02713683.2021.1878228 (a) SANTEN SAS, Evry, France - (b) SANTEN Pharmaceutical Co., Ltd., Osaka, Japan - (c) IRIS PHARMA, La Gaude, France - (d) OCULAR SURFACE & DRY EYE CENTER, University of Milan, Italy ⇒ Article #2017-206 Binding to ocular albumin as a half-life extension. Principle for intravitreally injected drugs: evidence from mechanistic rat and rabbit studies FUCHS H (a), IGNEY F (a) J. Ocul. Pharmacol. Ther. 2017; doi: 10.1089/jop.2016.0083 (collaboration) (a) BOEHRINGER INGELHEIM PHARMA GmbH & Co. KG, Biberach an der Riss, Germany #2015-197 Long-term tolerance of preservative-free eye drops containing macrogol hydroxystearate as an excipient Tolérance à long terme d’un collyre sans conservateur contenant comme excipient du macrogol hydroxystearate VIAUD K (a), LEFRANC-JULLIEN S (a), FERAILLE L (a), ELENA PP (a) J. Fr. Ophtalmol. 2015; doi: 10.1016/j.jfo.2015.09.011 (a) IRIS PHARMA, Nice, France ⇒ Abstract #2015-189 In vivo ocular tolerance of a new preservative-free eye drop formulation in rabbits QUENTRIC Y (a), VIAUD K (a), LEFRANC-JULLIEN S (a), FERAILLE L (a), ELENA PP (a) ARVO meeting 2015; Denver, CO - USA. ARVO e-abstract No. 802 - Poster D0264 (a) IRIS PHARMA, Nice, France ⇒ Poster ⇒ Abstract #2014-188 The effect of preservatives and antiglaucoma treatments on the ocular surface of mice with dry eye BARABINO S (a), ANTONELLI S (b), CIMBOLINI N (b), MAURO V (b), BOUZIN M (b) Invest. Ophthalmol. Vis. Sci. 2014; 55:6499-6504 doi:10.1167/iovs.14-14548 (a) CLINICA OCULISTICA, GENOCA, ITALY - (b) IRIS PHARMA, Nice, France ⇒ Abstract #2014-185 Plasma and ocular pharmacokinetic study comparing 3 µL micro-drop to typical 40 µL drop volume of timolol 0.5% in pigmented rabbits VAN DER HEIDEN H (a,b), AMAR T (c), LICHTENAUEUR W (a) ARVO meeting 2014; Orlando, FL - USA. ARVO e-abstract No. 453 - Poster D0072 (a) MU-DROP, Apeldoorn, Netherlands - (b) ZAMB, Hospital Pharmacy, Tilburg, Netherlands - (c) IRIS PHARMA, Nice, France ⇒ Abstract #2014-184 Ocular pharmacokinetic study comparing ramipril and ramiprilat formulations administered orally or topically in pigmented rabbits QUENTRIC Y (a), AMAR T (a), BARRE N (a), FERAILLE L (a), REKIK R (b) ARVO meeting 2014; Orlando, FL - USA. ARVO e-abstract No. 2360 - Poster B0036 (a) IRIS PHARMA, Nice, France - (b) OPHTHALMOLOGY CLINIC, Tunis, Tunisia ⇒ Abstract #2014-182 Biocompatibility of MedinGel biodegradable drug delivery system in the eye SPIS M (a), FERAILLE L (b), ANTONELLI S (b), CIMBOLINI N (b), ELENA PP (b), GAUDRIAULT G (a), PETIT A (a) Invest. Ophthalmol. Vis. Sci. 2014;55(13):5273. (a) MEDINCELL, Jacou, France - (b) IRIS PHARMA, Nice, France ⇒ Abstract #2013-179 Impact of the routes of administration on the effects of cyclosporine in an experimental rat model of dry eye CIMBOLINI N (a), GRILLO-ANTONELLI S (a), FERAILLE L (a), MARGARON P (a), ELENA PP (a) ISOPT meeting 2013; Paris – France (a) IRIS PHARMA, Nice, France ⇒ Poster #2013-178 CLS1001 suprachoroidal injectable suspension of triamcinolone acetonide is well tolerated in the albino rabbit VERHOEVEN R (a), VIAUD-QUENTRIC K (b), CACCIAMANI F (b), PATEL S (a) American College of toxicology 2013 San Antonio, Texas - USA. Poster P505 (a) CLEARSIDE BIOMEDICAL, Alpharetta, GA, USA - (b) IRIS PHARMA, Nice, France #2013-177 Suprachoroidal microinjection of triamcinolone acetonide is well tolerated in the albino rabbit VERHOEVEN R (a), PATEL S (a), VIAUD-QUENTRIC K (b), CACCIAMANI F (b), AMAR T (b), YERXA B (a) ARVO meeting 2013; Seattle, WA - USA. ARVO e-abstract No. 119 - Poster C0124 (a) CLEARSIDE BIOMEDICAL, Alpharetta, GA, USA - (b) IRIS PHARMA, Nice, France ⇒ Abstract #2012-169 Augmentation of the ocular penetration of dexamethasone with β-blocker and α-agonist co-administration ELENA PP (a), SENSEBY F (a), BERMON F (a), CHARFEDDINE R (b), REKIK R (c) EVER meeting 2012; Nice - France. Poster F107 (a) IRIS PHARMA, Nice, France - (b) UNIMED, Sousse, Tunisie - (c) Ophthalmology Clinic, Tunis, Tunisia ⇒ Abstract #2012-168 Anti-inflammatory effects of glucocorticoids on endotoxin-induced uveitis in rats: effects of the mode of administration ELENA PP (a), CIMBOLINI N (a), ANTONELLI S (a), DUBOS H (a), FERAILLE L (a), MARGARON P (a) ARVO meeting 2012; Fort Lauderdale, FL - USA. ARVO e-abstract No. 6285 - Poster D1145 (a) IRIS PHARMA, Nice, France ⇒ Poster ⇒ Abstract #2012-167 Assessment of intra-ocular pressure lowering effect of novel gel formulations of latanoprost and timolol in nonhuman primates following topical delivery GOODY RJ (a), WHITTAKER S (a), HENRY S (a), BROOKES R (a), STRUHARIK M (a), BERMON F (b), MARGARON P (b), POLZER H (c), LAWRENCE MS (a) ARVO meeting 2012; Fort Lauderdale, FL - USA. ARVO e-abstract No. 1968 - Poster D812 (a) RXGEN, Hamden, CT, USA - (b) IRIS PHARMA, Nice, France - (c) MEDPROJECT PHARMA, Bayern, Germany ⇒ Abstract #2010-157 Designing dendrimers for ocular delivery SPATARO G (a,b), MALECAZE F (c), TURRIN CO (a,b), SOLER V (c), DUHAYON C (a,b), ELENA PP (d), MAJORAL JP (a,b), CAMINADE AM (a,b) Eur. J. Med. Chem. 2010; 45: 326-334 (a) CNRS, Laboratoire de Chimie de Coordination, Toulouse, France - (b) Universite de Toulouse, Toulouse, France - (c) Hôpital Purpan, Toulouse, France - (d) IRIS PHARMA, Nice, France ⇒ Abstract #2009-156 Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation AKPEK EK (a), VITTITOW J (b), VERHOEVEN RS (b), BRUBAKER K (b), AMAR T (c), POWELL KD (d), BOYER JL (b), CREAN C (b) J. Ocul. Pharmacol. Ther. 2009; 25: 433-439 (a) THE WILMER EYE INSTITUTE, Johns Hopkins Hospital, Baltimore, USA - (b) INSPIRE PHARMACEUTICALS, Durham, USA - (c) IRIS PHARMA, Nice, France - (d) ENTHALPY ANALYTICAL, Durham, USA ⇒ Abstract #2009-153 Snapshot test for investigating gels of anti-glaucoma compounds as topical formulations ELENA PP (a), POLLIN C (a), BERMON F (a), AMAR T (a), CAILLAUD T (a), POLZER H (b) ARVO meeting 2009; Fort Lauderdale, FL - USA. ARVO e-abstract No. 6002 (a) IRIS PHARMA, Nice, France - (b) MEDPROJECT PHARMA, Bayern, Germany ⇒ Abstract #2007-148 Cationic oil-in-water emulsion as an improved cyclosporine ocular vehicle for vernal keratoconjuctivitis sicca (VKC) LAMBERT G (a), RABINOVICH-GUILATT L (a) ARVO meeting 2007; Fort Lauderdale, FL - USA. ARVO poster No. 2301/B999 (collaboration) (a) NOVAGALI PHARMA SA, Evry, France #2007-147 Ocular tolerability of iontophoresis ROY P (a), ELENA PP (b), VIAUD K (b), CAILLAUD T (b), CALIAS P (a) ARVO meeting 2007; Fort Lauderdale, FL - USA. ARVO e-abstract No. 5800 (a) EYEGATE PHARMACEUTICALS, Waltham, USA - (b) IRIS PHARMA, Nice, France #2007-145 Update on drug delivery systems used in the anterior part of the eye: review of the new drug delivery systems for the anterior chamber ELENA PP (a) ESCRS meeting 2007; Stockholm, Sweden. Oral presentation (a) IRIS PHARMA, Nice, France #2007-143 A new method for intra ocular pressure in vivo measurement: first clinical trials DUBOIS P, ZEMMOURI J, ROULAND JF, ELENA PP, LOPES R, PUECH P 29th IEEE EMBS Annual International Conference 2007; Lyon - France #2006-131 Pharmacokinetics of clonidine after a single application of transscleral iontophoresis in rabbits CAILLAUD T (a), ROY P (b), VIAUD K (a), ELENA PP (a) ARVO meeting 2006; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 2006; 47: ARVO e-abstract No. 5109 (a) IRIS PHARMA, Nice, France - (b) EYEGATE, Paris, France ⇒ Abstract #2006-130 Influence of solution composition and electrode design on transscleral iontophoresis delivery of dexamethasone disodium phosphate ROY P (a), VIAUD K (b), CAILLAUD T (b), ELENA PP (b) ARVO meeting 2006; Fort Lauderdale, FL - USA. ARVO e-abstract No. 5110 (a) EYEGATE, Paris, France - (b) IRIS PHARMA, Nice, France #2006-129 Evaluation of ocular tolerability of repetitive corneal-scleral iontophoresis in pigmented rabbits ELENA PP (a), ROY P (b), VIAUD K (a), CAILLAUD T (a) ARVO meeting 2006; Fort Lauderdale, FL - USA. ARVO e-abstract No. 5094 (a) IRIS PHARMA, Nice, France - (b) EYEGATE, Paris, France ⇒ Abstract #2005-124 Comparison of carteolol plasmatic levels after repeated instillations of long-acting and regular formulations of carteolol 2% in glaucoma patients RENARD P (a), KOVALSKI JL (b), COCHEREAU I (c), JAULERRY S (d), WILLIAMSON W (e), ELENA PP (f), LABLACHE COMBIER M (g), ALLAIRE C (g), SIOU-MERMET R (g) Graefe's Arch. Clin. and Exp. Ophthalmol. 2005; 243: 1221-1227 (a) Institut Vernes, Paris, France - (b) HIA Clermont Tonnerre, Brest, France - (c) CHRU, Angers, France - (d) CH Tarbes Vic Bigorre, Tarbes, France - (e) CH François Mitterrand, Pau, France - (f) IRIS PHARMA-CLIROPHTHA, Nice, France - (g) BAUSCH & LOMB, Paris, France ⇒ Abstract #2004-122 Ocular hypotensive effect of a new “once-daily” eye-dops formulation of 0.5% timolol (Timolast™) in comparison to Timoptol® 0.5% administered twice-daily ROULAND JF (a), MOREL-MANDRINO P (b), ELENA PP (b), DE GREGORIO F (c), BAROZZI C (c), FEDELI E (c), FERREIRA VD (c) ISOPT meeting 2004; Monte-Carlo – Monaco (a) Hôpital Huriez, Lille, France - (b) CLIROPHTHA, Nice, France - (c) TUBILUX PHARMA SpA, Roma, Italy #2004-121 Intérêt d’une nouvelle formulation de diclofénac sans conservateur pour la surface oculaire CHIAMBARETTA F (a), CREUZOT-GARCHER C (b), PILON F (a), POULIQUEN P (c), REBIKA H (c), DUBRAY C (d), RIGAL D (a) J. Fr. Ophtalmol. 2004; 27, 7, 739-744 (collaboration) (a) Hôpital Gabriel Montpied, Clermont-Ferrand, France - (b) CHU de Dijon, Dijon, France - (C) LABORATOIRES THEA, Clermont-Ferrand, France - (d) Unité de Pharmacologie Clinique, Centre de Recherche en Nutrition Humaine, Clermont-Ferrand, France ⇒ Article #2004-120 Comparison of once-daily nonpreserved timolol and timolol maleate gel-forming solution associated with latanoprost BRON A, VELASQUE L, REBICA H, POULIQUEN P, ELENA PP, ROULAND JF J. Fr. Ophtalmol. 2004; 27(9 Pt 1): 971-7 ⇒ Abstract #2004-119 Non-inferiority, in the intra-ocular pressure (IOP)-lowering effect, of a new eye-drops formulation of 0.5% timolol (Timolast™) instilled once-daily versus 0.5% Timoptol®, instilled twice-daily, for 4 months in ocular hypertensive or glaucomatous patients ROULAND JF (a), MOREL-MANDRINO P (b), DE GREGORIO F (c), BAROZZI C (c), FEDELI E (c) ARVO meeting 2004; Fort Lauderdale, FL – USA. Invest. Ophthalmol. Vis. Sci. 2004; 45: ARVO e-abstract No. 2080 (a) Hôpital Huriez, Lille, France - (b) CLIROPHTHA, Nice, France - (c) TUBILUX PHARMA SpA, Roma, Italy #2004-118 Comparison of carteolol plasmatic levels after repeated instillations of long acting and regular formulations of carteolol 2% in glaucomatous patients ALLAIRE CM, RENARD P, KOVALSKI J, COCHEREAU I, JAULERRY S, WILLIAMSON W, ELENA PP, LABLACHE-COMBIER M ARVO meeting 2004; Fort Lauderdale, FL – USA. Invest. Ophthalmol. Vis. Sci. 2004; 45: ARVO e-abstract No. 957 #2004-117 Efficacy and safety of diclofenac 0.1% ABAK® versus preserved diclofenac® 0.1% eye drops in controlling post-cataract surgery inflammation GOLDSCHMIDT P, ELENA PP, BALDWIN H, DELVAL L , COLIN J ARVO meeting 2004; Fort Lauderdale, FL – USA. Invest. Ophthalmol. Vis. Sci. 2004; 45: ARVO e-abstract No. 294 #2002-112 Timolol 0.1% gel (Nyogel 0.1%®) once daily versus conventional timolol 0.5% solution twice daily: a comparison of efficacy and safety ROULAND JF (a), MOREL-MANDRINO P (b), ELENA PP (b), POLZER H (c), SUNDER RAJ P (d) Ophthalmologica 2002; 216: 449-454 (a) Hôpital Huriez, Lille, France - (b) CLIROPHTHA, Nice, France - (c) MEDPROJECT PHARMA, Sauerlach, Germany - (d) NOVARTIS OPHTHALMICS, Farnborough, UK ⇒ Abstract #2001-109 A Novel Once-a-Day Timolol 0.1% Gel Formulation has an equivalent IOP-lowering efficacy to timolol 0.5% solution ROULAND JF (a), MOREL-MANDRINO P (b), ELENA PP (b), POLZER H (c) IGS meeting 2001; Prague - Czech Republic (a) Hôpital Huriez, Lille, France - (b) CLIROPHTHA, Nice, France - (c) MEDPROJECT PHARMA, Sauerlach, Germany #2000-106 A new long acting ophthalmic formulation of carteolol containing alginic acid SECHOY O (a), TISSIE G (a), SEBASTIAN C (a), MAURIN F (a), DRIOT JY (a), TRINQUANT C (a) Int. J. Pharm. 2000; 207: 109-116 (collaboration) (a) LABORATOIRE CHAUVIN, Montpellier, France ⇒ Abstract #2000-105 Therapeutic equivalence of a timolol 0.1% hydrogel (T-Gel 0.1%) QD and aqueous timolol 0.5% BID in reducting the IOP of glaucomatous patients ELENA PP, ROULAND JF, MOREL-MANDRINO P, POLZER H ARVO meeting 2000; Fort Lauderdale, FL – USA. Invest. Ophthalmol. Vis. Sci. 2000; 41: S281, abstract No. 2477 #2000-103 Comparison of the effects of preserved and unpreserved formulations of timolol on the ocular surface of albino rabbits PISELLA PJ (a,b), FILLACIER K (d), ELENA PP (e), DEBBASCH C (b,c), BAUDOUIN C (a) Ophthalmic Res. 2000; 32: 3-8 (a) Department of Ophthalmology, Ambroise Paré Hospital, APHP, Paris, France - (b) Toxicology Laboratory, University of Paris-V René Descartes, Paris, France - (c) Department of Cellular Pharmacotoxicology, XV-XX Hospital, Paris, France - (d) Department of Ophthalmology, University of Nice, France - (e) IRIS PHARMA, Nice, France ⇒ Article #2000-101 Evaluation of a novel carteolol eye-drops with alginic acid as long action promoter TISSIE G, SEBASTIAN C, MAURIN F, SECHOY O, DRIOT JY, ELENA PP, TRINQUAND C EVER meeting 2000; Palma de Mallorca, Spain. Ophthalmic Res. 2000; 32(S2): 29, abstract No. 214 #2000-100 Alginic acid effect on ocular distribution of carteolol after a single instillation in pigmented rabbits SEBASTIAN C, TISSIE G, DRIOT JY, ELENA PP, TRINQUAND C EVER meeting 2000; Palma de Mallorca, Spain. Ophthalmic Res. 2000; 32(S2): 28, abstract No. 215 #1997-86 Effects of different formulations of mitoxantrone (solutions, nanospheres, liposomes) on glaucoma surgery in rabbits TILLEUL P, DENIS P, MAIGNEN F, ELENA PP, NORDMANN JP, LEVERGE R, ROSTENE W Ophthalmic Res. 1997; 29: 218-226 ⇒ Abstract #1996-80 Antiproliferative activity of a liposomal delivery system of mitoxantrone on rabbit subconjunctival fibroblasts in an ex-vivo model MAIGNEN F, TILLEUL P, BILLARDON C, XU-VAN OPSTAL WY, PELAPRAT D, ELENA PP, DENIS P, ROSTENE W J. Ocul. Pharmacol. Ther. 1996; 12: 289-298 #1996-75 Assessment of the safety and local pharmacokinetics of 0.15 % gel of ganciclovir (Virgan®) in healthy volunteers POULIQUEN P (a), ELENA PP (b), MALECAZE F (c), LUYCKX J (a), LANOUE A (a), GOLDSCHMIDT P (d) ARVO meeting 1996; Fort Lauderdale, FL – USA. Invest. Ophthalmol. Vis. Sci. 1996; 37: S313, abstract No. 1431 (a) LABORATOIRES THEA, Clermont-Ferrand, France - (b) CLIROPHTHA, Nice, France - (c) Hôpital Purpan, Toulouse, France - (d) Centre Hospitalier Universitaire de la Pitié-Salpêtrière, Paris, France #1996-74 Ocular bioavailability of ganciclovir gel, an anti-herpetic formulation, after topical administration to intact or removed corneal epithelium of rabbit eyes KHOSRAVI E, ELENA PP, GOLDSCHMIDT P, LUYCKX J ARVO meeting 1996; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1996; 37: S81, abstract No. 383 #1994-60 Distribution of ganciclovir in the anterior uvea after topical application of 0.15 % ganciclovir gel to intact and HSV-infected eyes of rabbits ELENA PP, GOLDSCHMIDT P, CHAST F, SAUVAGEON H, LUYCKX J, KHOSRAVI E ARVO meeting 1994; Sarasota, FL - USA. Invest. Ophthalmol. Vis. Sci. 1994; 35: 1682, abstract No. 1984 #1993-56 Bioequivalence between timolol maleate formulated in ophthalmic solution (Timoptol®) and in a novel gel vehicle (T-Gel) ELENA PP, POLZER H, KHOSRAVI E ARVO meeting 1993; Sarasota, FL - USA. Invest. Ophthalmol. Vis. Sci. 1993; 34: 1490, abstract No. 3902 #1993-55 Ocular pharmacokinetics of topically-applied ganciclovir in rabbits with intact or removed corneal epithelium CHIBRET H, ELENA PP, KHOSRAVI E ARVO meeting 1993; Sarasota, FL - USA. Invest. Ophthalmol. Vis. Sci. 1993; 34: 1050, abstract No. 1712 #1992-50 Effect of diclofenac sodium and diclofenac sodium SDU eyedrops on prostaglandin concentrations in aqueous humor of rabbits after extracapsular surgery ELENA PP, ULRICH E, TSCHALAR Y, LAPALUS P, ETTAICHE M, KHOSRAVI E ISER meeting 1992; Stresa - Italy. Exp. Eye Res. 1992; 55: S54, abstract No. 183 #1992-49 Ocular pharmacokinetics of two preservatives, benzalkonium chloride or benzoxonium chloride, after instillation in the pigmented rabbit ELENA PP, KHOSRAVI E, LAPALUS P, ULRICH E ISER meeting 1992; Stresa - Italy. Exp. Eye Res. 1992; 55: S54, abstract No. 182 BASIC RESEARCH & REPORTS #2017-211 Transform your macroscope into an ultramacroscope for 3D imaging of cleared organs GESSON M (a), KECHAD M (b), MAUCLERT N (c), GIRARD P (c), ROUSSEL A (c), PIERRE O (d), GROSJEAN I (e), BRAU F (f) Focus on Microscopy meeting 2017; Bordeaux - France. Poster No P2-A/26 (a) CNRS, INSERM, Institut Biologie Valrose, Nice, France - (b) IRIS PHARMA, La Gaude, France - (c) OCA, Service de Mécanique Mutualisé, France - (d) IINRA, Institut Sophia Agrobiotech, Biot, France - (e) INSERM, Institut de Recherche sur le Cancer et le Vieillissement, Nice, France - (f) CNRS, Institut de Pharmacologie Moléculaire et Cellulaire, Valbonne, France #2016-205 Norbixin protects retinal pigmented epithelium cells and photoreceptors against A2E-mediated phototoxicity in vitro and in vivo FONTAINE V (a), MONTEIRO E (a), BRAZHNIKOVA E (a), LESAGE L (a), BALDUCCI C (b), GUIBOUT L (b), FERAILLE L (c), ELENA PP (c), SAHEL JA (a), VEILLET S (b), LAFONT R (b) PLOS ONE 11(12): e0167793. doi: 10.1371/journal.pone.0167793 (a) INSTITUT DE LA VISION, Paris, France - (b) BIOPHYTIS, Paris, France - (c) IRIS PHARMA, La Gaude, France ⇒ Article #2014-186 Regulatory Issues related to preclinical animal research ELENA PP (a) ARVO meeting 2014; Orlando, FL - USA. Oral communication (a) IRIS PHARMA, Nice, France #2012-175 Report of the TFOS/ARVO symposium on global treatments for dry eye disease: an unmet need SULLIVAN D (a), HAMMITT K (b), SCHAUMBERG D (c), SULLIVAN B (d), BEGLEY C (e), GJORSTRUP P (f), GARRIGUE JS (g), NAKAMURA M (h), QUENTRIC Y (i), BARABINO S (j), DALTON M (k), NOVACK G (l) The Ocular Surface. Special Article. April 2012; 10(2): 108-116 (a) SCHEPENS EYE RESEARCH INSTITUTE, Boston, MA, USA - (b) SJOGREN’s SYNDROME FOUNDATION, Bethesda, MD, USA - (c) BRIGHAM AND WOMEN'S HOSPITAL and HARVARD MEDICAL SCHOOL, Boston, MA, USA - (d) TEARLAB Corporation, San Diego, CA, USA - (e) SCHOOL OF OPTOMETRY, Bloomington, IN, USA - (f) RESOLVYX PHARMACEUTICALS, Bedford, MA, USA - (g) NOVAGALI PHARMA, Evry, France - (h) SANTEN PHARMACEUTICAL Co, Nara, Japan - (i) IRIS PHARMA, Nice, France - (j) CLINICA OCULISTICA, Genova, Italy - (k) DALTON & ASSOCIATES, Reading, PA, USA - (l) PHARMA LOGIC, San Rafael, CA, USA ⇒ Abstract #2011-164 Explorations et imagerie rétinienne BENCHABOUNE M (a) STO meeting 2011; Tunis - Tunisia. Oral Communication in French (a) IRIS PHARMA, Nice, France #2011-163 Adaptive optics imaging in age-related macular degeneration GOCHO-NAKASHIMA K (a), BENCHABOUNE M (b), ULLERN M (a), LAMORY B (c), CHATEAU N (c), SAHEL JA (a), PAQUES M (a) EVER meeting 2011; Crete - Greece. Oral Communication (a) INSERM 503, Paris, France - (b) IRIS PHARMA, Nice, France - (c) IMAGINE EYES, Orsay, France ⇒ Abstract #2011-162 In vivo microscopic imaging of drusen using adaptive optics LAMORY B (a), NAKASHIMA K (b), BENCHABOUNE M (b,c), ULLERN M (b), VUAILLAT E (a), SAHEL JA (b), PAQUES M (b) ARVO meeting 2011; Fort Lauderdale, FL - USA. ARVO e-abstract No. 4469/A218 (a) IMAGINE EYES, Orsay, France - (b) INSERM 503, Paris, France - (c) IRIS PHARMA, Nice, France ⇒ Abstract #2010-159 Dry Eye Syndrome: the regulatory challenge. Clinical trial and regulatory challenges faced by Iris Pharma in the development of dry eye therapies QUENTRIC Y (a) TFOS Global Dry Eye Experts' meeting 2010; Florence - Italy. Oral Communication (a) IRIS PHARMA, Nice, France #2010-158 Rôle des oligoéléments (Se, Zn) dans la prévention de la DMLA : le point en 2010 BENCHABOUNE M (a) SFVB/SFERETE/ATERET meeting 2010; Monastir - Tunisia. Oral Communication in French (a) IRIS PHARMA, Nice, France #2009-155 Associer les patients atteints de DMLA à la recherche, est-ce possible? BENCHABOUNE M (a) Vu et Entendu. 2009; 2: 4 (a) IRIS PHARMA, Nice, France ⇒ Article #2008-150 La recherche biomédicale en France : ce qui a changé depuis 2004 CLERGET-CHOSSAT N (a), CAILLAUD T (a) and ELENA PP (a) J. Fr. Ophtalmol. 2008; 31: 80-86 (a) IRIS PHARMA, Nice, France #2007-242 Comparaison in vivo de médicaments anti-allergiques avec microscope confocal afin d’évaluer la réponse tardive à l’anaphylaxie induit chez le cobaye FERAILLE L (a) AOP 2007 - S85 ; Paris - France. Oral communication in French (a) IRIS PHARMA, Nice, France #2007-225 Ether-Lipid-Deficient-Mice Display Pigmentary Glaucoma Features as Well as Abnormal Retinal Vasculature ACAR N (a), SICARD P (b), SCHNEBELEN C (a), CIMBOLINI N (c), IVINGS L (a), GRILLO-ANTONELLI S (c), ROCHETTE L (b), CREUZOT-GARCHER CP (a,d), BRETILLON L (a), JUST WW (e) ARVO meeting 2007; Fort Lauderdale, FL - USA. Investigative Ophthalmology & Visual Science May 2007, Vol.48, 2978. doi: (a) INRA, Dijon, France - (b) Faculties of Medicine and Pharmacy, Dijon, France - (c) IRIS PHARMA, Nice, France - (d) University Hospital, Dijon, France - (e) Biochemie Zentrum Heidelberg (BZH), Heidelberg, Germany #2006-142 The role of the CROs in the ophthalmological drug development in Europe ELENA PP (a) Oral presentation. ISOPT meeting 2006; Berlin, Germany (a) IRIS PHARMA, Nice, France #1996-79 The renin-angiotensin system in the rabbit eye RAMIREZ M, DAVIDSON EA, LUTTENAUER L, ELENA PP, CUMIN F, MATHIS GA, DE GASPARO M J. Ocul. Pharmacol. Ther. 1996; 12: 299-312 #1995-67 The renin-angiotensin system in the rabbit eye RAMIREZ M, DAVIDSON EA, ELENA PP, MATHIS GA, DE GASPARO M ISECOPP meeting 1995 Geneva - Switzerland, p. 25 #1994-64 Correlation between anterior chamber inflammation and proliferative vitreoretinopathy in the rabbit KHOSRAVI E, BAUDOUIN C, ELENA PP JERMOV meeting 1994; Montpellier - France, p 240, abstract No. P192 #1994-63 Central nervous system control of intraocular pressure DENIS P, NORDMANN JP, ELENA PP, SARAUX H, LAPALUS P Fundam. Clin. Pharmacol. (France) 1994; 8: 230-237 #1993-57 Physiological roles of dopamine and neuropeptides in the retina DENIS P, NORDMANN JP, ELENA PP, DUSSAILLANT M, SARAUX H, LAPALUS P Fundam. Clin. Pharmacol. (France) 1993; 7: 293-304 ⇒ Abstract #1991-47 La radioautographie en ophtalmologie : méthodologie et applications à l'étude des récepteurs oculaires et à l'hybridation in situ DENIS P, ELENA PP, NORDMANN JP, DUSSAILLANT M, LAPALUS P, SARAUX H, ROSTENE W "Physiologie, Pathologie et Génétique Oculaire." CHRISTEN Y AND DROIX-LEFAIX MT ed. (Springer Verlag, Paris, 1991), 105-113 #1991-46 Localisation et caractérisation radioautographiques des récepteurs β-adrénergiques oculaires dans les structures non pigmentées chez l'homme LAPALUS P, ELENA PP, NORDMANN JP, LAROCHE L, SARAUX H, LAPALUS P Ophtalmologie (France) 1991; 5: 53-56 #1991-45 Localization and characterization of substance P binding sites in rat and rabbit eyes DENIS P, FARDIN V, NORDMANN JP, ELENA PP, LAROCHE L, SARAUX H, ROSTENE W Invest. Ophthalmol. Vis. Sci. 1991; 32: 1894-1902 ⇒ access to the abstract #1991-44 Autoradiographic characterization and localization of vasoactive intestinal peptide binding sites in albino rat and rabbit eyes DENIS P, DUSSAILLANT M, NORDMANN JP, ELENA PP, SARAUX H, ROSTENE W Exp. Eye Res. 1991; 52: 357-366 #1991-43 Autoradiographic localization of β-adrenergic binding sites in human retinal blood vessels DENIS P, ELENA PP, LAPALUS P Chibret Int. J. 1991; 7: 14-19 #1991-42 Distribution rétinienne des sites récepteurs dopaminergiques rétiniens chez l'homme. Hypothèses fonctionnelles sur le rôle de la dopamine dans la vision DENIS P, NORDMANN JP, ELENA PP, LAPALUS P (Dopamine, Fonctions Cérébrales et Neurosensorielles; Budapest - Hungary 1991) Euthérapie #1990-41 Autoradiographic localization of D1 and D2 dopamine binding sites in the human retina DENIS P, ELENA PP, NORDMANN JP, SARAUX H, LAPALUS P Neurosci. Lett. 1990; 116: 81-86 #1990-40 ß-adrenergic binding sites in the human eye: an autoradiographic study ELENA PP, DENIS P, KOSINA-BOIX M, SARAUX H, LAPALUS P J. Ocul. Pharmacol. 1990; 6: 143-149 #1990-39 Localisation et caractérisation autoradiographiques de sites de liaison oculaires du VIP (Vasoactive Intestinal Peptide) chez le rat et le lapin albinos DENIS P, DUSSAILLANT M, ELENA PP, NORDMANN JP, ROSTENE W, LAROCHE L Ophtalmologie (France) 1990; 4: 30-32 #1990-35 Specific receptors to vasculotropin in the eye MOUKADIRI H, DENIS P, ELENA PP, ROSTENE W, PLOUET J AER meeting 1990, Bad Honnef - Germany, p 24, abstract No. 4 #1990-33 Autoradiographic localisation of insulin binding sites in the human eye DENIS P, ELENA PP, LE MARCHAND-BRUSTEL Y, NORDMANN JP, LAPALUS P, SARAUX H ISER meeting 1990, Helsinki - Finland, p 114, abstract No. 384 #1990-31 Localisation et caractérisation radioautographiques des récepteurs ß-adrénergiques oculaires dans les structures non pigmentées chez l'homme DENIS P, ELENA PP, NORDMANN JP, SARAUX H, LAPALUS P SFO meeting 1990, Paris – France #1990-30 La radioautographie en ophtalmologie : méthodologie et applications à l'étude des récepteurs oculaires et à l'hybridation in situ DENIS P, ELENA PP, NORDMANN JP, ROSTENE W, LAPALUS P Séminaires Ophtalmologiques IPSEN, Royaumont - France 1990 #1989-28 Localisation autoradiographique des récepteurs dopaminergiques rétiniens chez l'homme. Implications fonctionnelles DENIS P, NORDMANN JP, ELENA PP, LAROCHE L, LAPALUS P Bull. Soc. Ophtalmol. Fr. (France) 1989; 89: 807-810 #1989-27 Récepteurs béta-adrenergiques vasculaires rétiniens chez l'homme DENIS P, ELENA PP Ophtalmologie (France) 1989; 3: 62-64 ⇒ access to the abstract #1989-26 Dopamine receptors in rabbit and rat eye: characterization and localization of DA1 and DA2 binding sites ELENA PP, DENIS P, KOSINA-BOIX M, LAPALUS P Curr. Eye Res. 1989; 8: 75-83 #1989-25 Alpha2-adrenergic receptors in rat and rabbit eye: a tritium-sensitive film autoradiography ELENA PP, KOSINA-BOIX M, DENIS P, MOULIN G, LAPALUS P Ophthalmic Res. 1989; 21: 309-314 #1989-24 Localisation of angiotensin-converting enzyme (ACE) in rat ciliary process by autoradiography and immunocytochemistry LALIBERTE F, ELENA PP, LALIBERTE MF, LAPALUS P, CHEVILLARD C AER meeting 1989, Montpellier - France, Doc. Ophthalmol. 1990; 76: 194-195, abstract No. 167 #1989-23 Beta-adrenergic receptors in human eye sections ELENA PP, DENIS P, LAROCHE L, LAPALUS P AER meeting 1989, Montpellier - France, Doc. Ophthalmol. 1990; 76: 194, abstract No. 166 #1989-22 Autoradiographic localization of vasoactive intestinal peptide binding sites in albino rabbit and rat eye DENIS P, DUSSAILLANT M, NORDMANN JP, ELENA PP, ROSTENE W, SARAUX H AER meeting 1989, Montpellier - France, Doc. Ophthalmol. 1990; 76: 159-160, abstract No. 104 #1989-21 Autoradiographic localisation of insulin receptors in the human eye ELENA PP, DENIS P, LE MARCHAND-BRUSTEL Y, LAPALUS P AER meeting 1989, Montpellier - France, Doc. Ophthalmol. 1990; 76: 158-159, abstract No. 102 #1989-18 Piribedil and retinal dopaminergic binding sites LAPALUS P, ELENA PP, DENIS P, FREDJ-REYGROBELLET D World Congress of Neurology 1989, New Dehli - India #1989-17 Localisation autoradiographique des récepteurs dopaminergiques rétiniens chez l'homme. Implications fonctionnelles DENIS P, NORDMANN JP, ELENA PP, LAROCHE L, LAPALUS P SFO meeting 1989, Paris - France #1988-16 Neurotransmitters and intraocular pressure LAPALUS P, ELENA PP Fundam. Clin. Pharmacol. (France) 1988; 2: 305-325 #1988-15 Autoradiographic localization of beta-adrenergic binding sites in human blood retinal vessels ELENA PP, DENIS P, LAPALUS P ISER meeting 1988, San Francisco, CA - USA #1988-14 Autoradiographic characterization of D-1 and D-2 receptors in rat, rabbit and human Eyes ELENA PP, DENIS P, LAPALUS P ISER meeting 1988, San Francisco, CA - USA #1987-13 Autoradiographic localization of ß-adrenergic receptors in rabbit eye ELENA PP (a), KOSINA-BOIX M (b), MOULIN G (a), LAPALUS P (b) Invest. Ophthalmol. Vis. Sci. 1987; 28: 1436-1441 (a) Laboratoires DULCIS ALLERGAN, Monaco - (b) the Laboratoire de Pharmacologie Faculte de Medecine, Nice, France ⇒ access to the abstract #1987-12 Dopamine DA1 receptors in the eye: characterization and localization of 125I-SCH 23982 binding sites ELENA PP, KOSINA-BOIX M, LAPALUS P AER meeting 1987, Leuven - Belgium #1986-10 Monoclonal antibodies to human amnion recognize different components of the rabbit eye HSI BL, FREDJ-REYGROBELLET D, YEH CJG, ELENA PP, MOULIN G, LAPALUS P Invest. Ophthalmol. Vis. Sci. 1986; 27: 620-622 ⇒ access to the article #1986-9 Système alpha-adrenergique et pression intra-oculaire LAPALUS P, ELENA PP Rencontres Internationales de Chimie Thérapeutique, Clermont-Ferrand - France 1986 #1986-8 Autoradiographic localization of ß-adrenergic receptors in rabbit eye ELENA PP, KOSINA-BOIX M, MOULIN G, LAPALUS P AER meeting 1986, Oxford - UK #1985-7 Embryological studies of rabbit eye by using monoclonal antibodies FREDJ-REYGROBELLET D, HSI BL, MOULIN G, YEH CJG, ELENA PP, LAPALUS P AER meeting 1985, Leysin - Switzerland, p 61 abstract No. 73 #1985-6 Alpha-adrenoceptors in rabbit iris-ciliary-body (ICB) membranes: characterization and localization with 3H-clonidine ELENA PP, PALTRINIERI P, MOULIN G, FREDJ-REYGROBELLET D, LAPALUS P AER meeting 1985, Leysin - Switzerland, p 56 abstract No. 62 #1984-5 Pharmacological characteristics of β-adrenergic-sensitive adenylate cyclase in non pigmented and pigmented cells of bovine ciliary process ELENA PP, FREDJ-REYGROBELLET D, MOULIN G, LAPALUS P Curr. Eye Res. 1984; 3: 1383-1389 #1984-4 Characterization of β-adrenergic receptors in bovine pigmented ciliary processes ELENA PP, MOULIN G, LAPALUS P Curr. Eye Res. 1984; 3: 743-750 #1984-1 Adenylate cyclase activity in non pigmented (NPE) and in pigmented (PE) cells of bovine ciliary process ELENA PP, FREDJ-REYGROBELLET D, MOULIN G, LAPALUS P ISER meeting 1984, Alicante - Spain, p.95 #1984-232 Wound healing of different epithelia in albino rabbit eye anterior segment FREDJ-REYGROBELLET D, MOULIN G, ELENA PP, LAPALUS P ISER meeting 1984, Alicante - Spain, p.95 Have questions or need help with your ophthalmology development programs ? Ask Our Experts Iris Pharma A leading contract research organization (CRO) dedicated to ophthalmic research, Iris Pharma partners with clients to carry out preclinical research and clinical studies involving all areas of the field, from the ocular surface to the posterior segment of the eye. View More Preclinical development In vivo Pharmacology Studies GLP Ocular Tolerance & Safety GLP Ocular Pharmacokinetics Equipment Early testing Efficacy & Proof of Concept Early Pharmacokinetics Pilot Tolerance & Safety Testing Formulation & Delivery Clinical Trials Clinical Trial Services Ophthalmic Indications Clinical Trial Phases Countries About Iris Pharma Who We Are Services Ocular Expertise Publications News & Media Events Legal notice - Sitemap - Contact us Copyright 2021 - Iris Pharma - ckc-net.com This website intends to use cookies to improve the site and your experience. By continuing to browse the site you are agreeing to accept our use of cookies. If you require further information and/or do not wish to have cookies placed when using the site, visit Use of cookies Accept cookiesRefuse cookies